20160210 RELEASE 5MIAMIBEACH
€ity of Miomi Beqch, I200 Convention Center Drive, Miomi Beoch, Florido 33139, www.miomibeochfl.gov
MEMORANDUMTo: Mayor Philip Levine and Members of the City Commission
FROM: Rafael E. Granado, City Clerk
DATE: February 9,2014
SUBJECT: City Commission At-Large Nominations for February 10, 2016, - Release # 5
Below please find the City Commission At-Large Nominations received to date for the February
10, 2016 Commission Meeting. Changes made since Release # 4, ate shown in red.
BOARD AND COMMITTEES
1. AFFORDABLE HOUSTNG ApVtSORy COMMTTTEE VACANCTES (6):
c Beth B. Butler (Release # 1, Page 5)o Nominated for appointment (citizen who represents employers within the jurisdiction) by
Commissioner Grieco. (Release # 3, Page 1 - category change)
o Janie P. Hayes (Release # 1 , Page 13)o Nominated for appointment (citizen actively engaged as an advocate for low-income
persons in connection with affordable housing) by Commissioner Rosen Gonzalez.
o Francis (Frankie) Trullenque (Release # 1, Page 21)o Nominated for appointment (citizen actively engaged as an advocate for low-income
persons in connection with affordable housing) by Vice-Mayor Alem6n.o Nominated for appointment (citizen actively engaged as an advocate for low-income
persons in connection with affordable housing) by Commissioner Malakoff. (Release # 2,
Page 1)o Nominated for appointment (citizen actively engaged as an advocate for low-income
persons in connection with affordable housing) by Mayor Levine. (Release # 3, Page 1)
o Nominated for appointment (citizen actively engaged as an advocate for low-income
persons in connection with affordable housing) by Commissioner Arriola. (Release # 3,
Page 1)
o Jeffrey M. Feldmano Nominated for appointment (citizen who actively serves on the local planning agency
pursuant to F.S. S 163.3174 [Planning Board Member]) by Commissioner Grieco.
(Release # 4, Page 5)
2. BUDGET ADVISORY COMMTTTEE VACANCy (1):
No nomination received do date.
1
3. HEALTH ApVtSORy COMMTTTEE VACANCTES (3):
o Dr. Todd M. Narson (Release # 1, page 2g)o Nominated for reappointment (health benefits provider) by Commissioner Malakoff.o Nominated for reappointment (health benefits provider) by Vice-Mayor Alem6n.
(Release #2, Page 1)
. Dr. Nchard M. Awdeh (Release # 5, page 5)o Nominated for reappointment (corporate individual) by Commissioner Malakoff.
o Dr. Anthony J. Japour (Release # 5, Page 17)o Nominated for reappointment (administrator from an ACLF/ALF) by Commissioner
Malakoff.
4. |A IIIIIIIIIIIIIII BEACH HUMAN RtcHTS COMMTTTEE VACANCy (1):
o Clare F. McCord (Release # 1, Page 4l)o Nominated for appointment by Vice-Mayor Alemdn.o Nominated for appointment by Commissioner Arriola.o Nominated for appointment by Commissioner Malakoff.o Nominated for appointment by Commissioner Rosen Gonzalez.o Nominated for appointment by Commissioner Grieco. (Release # 2, Page 1)
2
Dr. Richard M. Awdeh
3
THIS PAGE INTENTIONALLY LEFT BLANK
4
g MtAMlsrfrH o CITY OF MIAMI BEACH
BOARD AND GOMMITTEE APPLICATION FORM
NAME: Awdeh Richard
Last Name
HOMEADDRESS:
First Name
Mlaml Beach
Middle Initial
33r39
Apt No. Home No./Street City
PHONE:
Home Work
Business Name: Btacom Patmer Eye lmutute Position: Physlclan
Address: 900 NW 17th Street Mlami
StaE Zip Code
rlchard.awdeh@gmai l.com
Emai! Address
FL 33't36
Street State Zip Code
Pusuant to Clty Code sectlon 2-22111a and b: Members of agencies, boards, and committees shall be afiiliated with the city; this
requirement shall be fulfilled in the following ways: a) an individual shall have been a resident of the city for a minimum of six
months; or b) an individual shall demonstrate ownership/interest for a minimum of six months in a business established in the city.
o Resident of Miami Beach for a minimum of six (6) months Yes
o Demonstrate an ownership/interest in a business in Miami Beach for a minimum of six (6) months: No
. Are you a registered voter in Miami Beach: Yes
o (Please dfcle one): I am now a resident of: South Beach
o I am applying for an appointment because I have special abilities, knowledge and experience. Please list below:
I am a physiclan ln illaml.
o Are you presently a registered lobbyist with the City of Miami Beach? l{o
Please list your preferences in oder of ranking [] first dtoice [2] second cttoice, and [3] third choioe. Please note that only thrce (31
cholces will be observed by the Glty Clerk'g Crfflce. (Regular Boards of City)
Cholce l: Health Advisory Committee
Cholce 2:
Choice 3:
Note: lf applying for Youth Advisory Board, please indicate your affiliation with the Scott Rakow Youth Center:
1 , Past serviee on the Youth Center Advisory Board: tr1o years of Service:
2. Present participation in Youth Center activities by your children No if yes, please list the names of your children, their
ages, and which programs. List below:
o Have you ever been convicied of a felony: No lf yes, please explain in detail:
City
o Do you cunently have a violation(s) of City of Miami Beach codes: No lf yes, please explain in detail:
o Do you cunently owe the City of Miami Beach any money: No lf yes, please explain in detail:
o Are you cunently serving on any City Boards or Committees: No lf yes, wtridr board?
o What organizations in the City of Miami Beacfi do you cunently hold membership in?
o List all properties owned or have an interest in, which are located within the City of Miami Beach:
o I am now employed by the city of Miami Beach: No lMrich department?
5
rhe rotlowrns lnromatlon tr voy*i""?,iJl."Fn:{rr#;lll"rrtT,l,ll1::n nor hag tnv be.rins on lonslaer.uon ror appo.ntment. lt lr
belng acked to comply x'[rr
Gender: Male
Race/Ethnic Categories
What ls your race? Mark one or morc raoes to indicate what you consider yourself to be. Whlte
Other Description:
Are you Spanish/Hispanic/ Latino? Mark the "No" box if not Spanish / Hispanic / Latino. No
PhysicallyChallenged: No
NOTE: lf appolnted, you wlll bc rcqulrcd to lollow certrln lawr wlrlch apply to ctty boerdlcommlttee memberu.
These law! lnclude, but.no not llmlted to, tfie followlng:
o ProhibiUon ftom directy or lndirectly lobbying city personnel (Miami Beacfi City Code s€dion 2-{59).o Pohibition from contracting with the city (Miaml-Dade County Code section 2-1 t .l ).o Pmhibilion hom lobbylng before board/commatteo you have serued on for perlod of one year after leaving offce (Miaml
Beach Codo section 2-26).o Requirement to disclose certain financlal lnterests and gifrs (Miami-Oade County Code seciion 2-t 1.1).
(re: CMB Community Development Advisory Committee): prohibition, during tenure and for one year alter leaving offce,
ftom having any interest in or receiving any benefit from Community Developmenl Block Grant funds for either yourself,
or thos6 with whom you have business or immediate family ties (CFR 570.61t).
Upon rcqucrt, copler of there hwt may be obtalned from thr Clty Clerk.
l'!..hete-by .ttest !o ths accurecy and truthfulnesr ol the .ppllc.Uon rnd hevc rccclved, ,€ad lnd wlt! abide by Chaptcr 2, Artlcle
Vll - of the Clty Code "Standards of Gonduct for Ctty Olfhon, Employcer rnd Agency ilemben."
I Rlchard Awdeh agreed to tlte followlng terms on
Received in the City Clerks Oflice by:
Name of Deputy Glerk Control No.Date
6
Rlchard M. Awdeh, M.D.-l
Richard M. Awdeh M.D.
CURRENT POSITION:
Unlted States, Food and Drug Admlnlstratlon
Clrle
Founder, Chlef Executlve Officer
CheckedUp
Founder, Chlef Erecutive Ofllcer
Bascom Palmer Eye lnstitute, Unlversity of Mlami
Asslstant Professor of Ophthalmology
Asslstant Professor of Pathology
Asslstant Professor of Molecular Blology and Biochemistry
Executive Mediclne, Ophthalmology
Dlrector, Technology Transfer ln Ophthatmology
2012
Team Ophthalmologlst, Universtty of Mlaml Hurrlcanes
Team Ophthalmologlst, Miami Marllns
MEDICAL TRAINING:
Bascom Palmer Eye tnstltute
Fellow, Cornea and Refractlve Surgery. Post Gnduate Year - V Fellowship Training
Duke Unlverslty, Depanment of Ophthalmology
Resident, Ophthalmology. Post Gnduate Year - ll - lV Residency Training. Wnner Duke Ocular lnnovation Award
Memorial Sloan-Ketterlng Cancer Center
lnternshlp, lnternal lttledlclne. Posl Graduate Year - I Residency Tnining
EDUCATION:
Yale Unlverslty, School of Medlclne
Doctor of Medlclne
Washington, DC
Chalrman, Dermatologlc and Ophthalmic Drugs Arlvlsory Committee Jan 2015 - Jan 2019
. Board Certified, United States Medical Licensilg Exam (USMLE) Step I, Step 2 & Step 3
. Medical School Thesis Project: Treatmeut of Optic Pathway Gliomas (tlonors)
. Presideut. American Medical Associatiou, Snrdent Cbapter, Yalc University
. Yale Student Research Grart Recipient - Suqmer 2001, Spring 2003
Emory Unlverslty
Golzueta Buslness School
. Valedictoriau of Emory Business School
. Sruuua Cum Laude, Highest Honors. Coomencement speaker
Miami, Florida
Nov 2011 - Present
New York, NY
Dec2012- Present
Miami, Florida
July 2009 - Present
July 2009 - July
Miami, Flodda
July 2008 - July 2009
Durham, North Carolina
July 2005 - June 2008
New York, New Yotk
June 2004 - June 2005
New Haven, Connecticut
August 2000 - May 2004
Atlanta, Georgia
August 1995 - May 1999
7
Rlchard M. Awdeh, rl.D.-2
London School of Economlcs, July 1997 London, England. Intcrnational Business Strategy Course concentrating on topics of European Monetary Union, rout€s for achicving
international expansion, and managing a multi-national corporation.
Haruard Unlversltyt Graduate ScDool of Eusiness
Summer Venture in llanagament Program, June 1998 Boston, Massachusetts. Focused on entrepreneurial management and the dynamics of teams in today's work environment.
RESEARCH FUNDING:
Natlonal lnstitutes of Health I Natlonal Eye lnstitute
Molecular in vivo lmaging of ophthalmic tumors
R21 EY02091041 September 2010 - September
2012
" o)(1)
2008
Carl Zeiss AG Research Grant
Research to Prevent Bllndness Resldent Support
Yale School of Mediclne Sfudent Research Grant
Yale School of liledlclne Studenf Research Grant
2003
2008
2001
HEALTH RELATED EXPERIENCE:
2008 Paul Kayser lnternatlonal Scholar Buenos Aires, Argentina
Awaded by the Pan-American Assocration of Ophthalmology, December 2007
United Sfates Food and Drug Admlnlstratlon
Centcr for Drug Evaluation and Rcssarch - Resident Medical Officcr, Summer 2007. Acted in the capacity of a Mcdical Offrcer (MO) in a multi-disciplinary tcam including pharmacologists,
microbiologists, chemists, statisticians, compliance officers and physicians in the evaluation of new ophthalmic
drugs.. Criticatly analyzed Investigational New Drug (IND) and New Drug Application (NDA) clinical trial design and
statistical methods for Phase I, II, and III trials.. Participated in industry conference calls and meetings regarding clinical trial dcsign, methods, and results.. Completed courses in clinical trial design and statistical mcthods.
Yale MD Thesis Prolect I St. Jude's Chlldren Research Hospltal
Glinical Researcher. See description above.
Bascom Palmer Eye lnstitute, Unlverslty of Mlaml
Visiting Rcsident, Orbital Oncology/Oculoplastics Service, November 2004
Doheny Eye lnstitute, Unlversity of Southern Callfornla
Visiting Medical Student / Researcher, Summer 2003. Contributed to sevcral clinical research projects in ophthalmology including the Intraocular Retinal Prosthesis
2005-
Summer
Summer
8
Rlchard M. Awdeh, M.D.-3
Project, 25-Guage Sutureless Vitrectomy Surgery, and patient Quality of Life following retinal surgcry.
Emory Unlverslty Scfool ol lledlclne
Basic Science Rcsearcher, August 1999 - May 2000
' Conducted research on Nuclear Porc Complex, specifically studying the role of protein NUP 98 in transport both
into and out of nucteus in a Xenopous system. Gained basic science bench skills including running Westem Blots,
polyacrytamide gels, Polymerase Chain Reaction (PCR), protein aflinity columns, and protein "r.uyt.
PRIOR WORK EXPERIENCEi
Arthur Andersen, LLP.
Summer Analyst, Summer 1998
Goldman, SacDs l3 Co.
Research Analyst, Fall 1997
Summer Analyst, Summer 1997
PROFESSIONAL SOCIETIES:
. American Board of Ophthalmology (ABO), Diplomate
. American College of Ophthalmic Surgeons (ACOS), 2010 - Present (Founding Membcr). American Acadcmy of Ophthalmology (AAO),2005-Present
. Comeal External Disease and Rcfractive Surgeons (CEDARS), 2012 - Present (Founding Membcr). Association for Rcscarch in Vision and Ophthalmology (ARVO), 2003-Present. American Medical Association, 2000-Present. American Society of Cataract and Refractive Surgeons (ASCRS) and American Socicty of Ophthalmic
Administrators, 2005-Prcsent. Sports Ophthalmology Society of thc Americas, Founding Board, 2005-Present. North Carolina Medical Society, Member. North Carolina Ophthalmology Society, Member
RESEARCH:
Courses Tausht:
Awdeh RM, Donnenfeld E, Slade S, Dell S, Culberston W, Krueger, R, Trattler, W, Kilic, A. Femtosecond laser cataract surgery.
American Society of Cataract and Refractivc Surgeons. Boston, MA, October, 2014.
Dunbar M, Awdeh, RM. Breaking News from Bascom Palmer. SECO, Ncw Orlcans, LA, March 2014.
Awdeh RM, Trattler, W, Donnenfeld, E. DiSital Tools for Patient Education and Communication. American Society of Ophthamic
Administrators. Boston, MA, October, 2014.
Awdeh RM, Donnenfeld E, Slade S, Dell S, Culberston W, Krueger, R, Trattler, W, Kilic, A. Fcmtosecond laser cataract surgery.
American Society of Cataract and Refractive Surgeons. San Francisco, CA, April 2013
Awdeh RM, Slade S, Dell S, Trattler W, Culbertson W, Nichamin S. Femtosecond laser cataract surgery. American Academy of
Ophthalmology. Orlando, FL, October, 201l.
Awdeh RM, Slade S, Dell S, Trattler W, Culbcrtson W, Nichamin S. Fcmtosecond laser cataract surgcry. American Society of
Cataract and Refractive Surgeons. San Diego, CA, March 27,2011.
Toyos R, O'Bricn TP, Sciller B, Awdeh RM, Trattler H. Vision and Sports: Sports Ophthalmology Society of the Americas.
Amcrican Society of Cataract and Refractive Surgeons. Chicago, tL, April 7, 2008.
Toyos R, Kim T, O'Brien TP, Mah FS, Schuler W, Awdeh RM, Trattler WB. Vision and Sports: Sports Ophthalmology Socicty of the
Americas. American Society of Cataract and Refractive Surgeons. San Diego, CA, May 1,2007.
9
Rlchard ll. Awdeh, M.D.4
Biomedical Engineering: Design in Biotechnology, Duke University, Spring 2006 - Teacher's Assistant
Led a team of engineering students in the design and development of a novel devico for intraocular pressure measurements.
Yale School of Medlclne Thesls:
Awdeh RM. Visual Outcome using Conformal Radiation Therapy versus Chemotherapy versus
Surgery in the treatment of Optic Pathway Gliomas.
Book Chapters:
Awdeh RM, Lakhanpal RR, Humayun MS. "Artificial Vision, Visual Prostheses & Retinal Implants" in Tano Y,
Alfaro DV, Liggett PE, Micler WF, Quiroz-Mercado H, Jager RD ed. Ase-related Macular Deseneration: A
Comorehensive Textbook. Lippincott, Williams & Wilkins. October l, 2005.
O)t/0
Peer.Revlewed Sclentlflc Paoers :
de laZerda, A, Prabhulkar, S, Perez, VL, Ruggeri, M, Paranjape, AS, Habte, F, Gambhir, SS, Awdeh, RM. Optical
Coherence contrast imaging using gold nanorods in living mice. Clinical and Experimental Ophthalmolog,2014.
Awdeh, RM, Kiehna, EN, Drewry, RD, Kerr, NC, Haik, BG, Wu, S, Xiong, X, Merchant, TE. Visual Outcomes in
Pediatric Optic Pathway Glioma aftcr Conformal Radiation Therapy. Intertational Journal of Radiation Oncologt,
2012,84(t). 46-5t.
Prabhulkar S, Matthews J, Rawal S, Awdeh RM. Molecular Histopathology Using Gold Nanorods and Optical
Coherence Tomography. Investigalive Ophthalmologt & Visual Science,20l3,54(2), I192-l2OO.
Prabhulkar S, de [a Zerda A, Paranjape A, Awdeh RM. Single Step Nanoplasmonic Immunoassay for the
measurement of protein biomarkers. Bios ensors. 20 I 3, 3( I ), 77-88.
Awdeh RM, Vroman DT, Ying MS, Coldman D, Kymionis G, Yoo SH. Phototherapeutic keratectomy for
treatment of subepithelial fibrosis and anterior comeal scarring following Dcscemet's stripping automated
endothel ial keratoplasty. C orne a. 20 I 2 luly, 3 I (7), 7 6 I -7 63.
Trattler WB, Awdeh RM, Albe E. The Ballots Are in. The all-time most-viewed videos on Eyctube.net. Cataract &
Reftactive Surgery Today. February 20 I I . Pages I 9-20.
Awdeh, RM, Alfonso, E, Humayun MS. Ophthalrnic Innovation: Thc cycs have it. Medical Innovation and
Business. 2( I ): I 0- 14, Spring 20 I 0. (Featured, Covcr Article)
Awdeh RM, Trattler WB, It's All in the Details. Exploring the fine points on Eyetube net. Cataract & Refractive
Surgery Today. September 2010. Pages 25-26.
Awdeh, RM, Alfonso, E, Humayun MS. Ophtalmic Innovation and thc Venture Capital Space, Cataract and
Refractive Surgery Today: Innovation 2010. lanuary, 2010. (Featured Article to Book)
Awdeh RM, Galchus S, Deramo V, Stinnett S, Lee P, Fekrat S. Vision-related quality of lifc in pcrsons with branch
retinal vein occlusion (BRVO) using the 25-Item NEI Visual Function Questionnaire . Br J Ophthalmol. 2010 Mar 94
(3 ).
Awdeh RM, Boggiano C, Goldbcrg DF, Stan CE, Stein J. What Type of Practice Does One Choose? Physicians and an
employment spccialist discuss carccr options. Cataract & Refractivc Surgery Today. November 2009. Pages 40-45.
Awdeh RM, Korcishi AF. Are donor comeoscleral rim cultures in penetrating keratoplasty clinically relevant?
American Academy of Ophthalmology Current Insight. Q3, July 23,2008.
10
Rlchard M. Awdeh, tr.D.-s
Awdeh RM, DeStefano JJ, Blackmon DM, Cummings TJ, Kim T. The Presence of T-lymphocyte
Subpopulations (CD4 and CD8) in Ptcrygia: Evaluation of the lnflammatory Response. Adv Ther 2008
Sep-Oct; 25(5):47 9-87 .
Awdeh RM, Galchus S, Dcramo V, Stinnett S, Lee P, Fekrat S. Vision-related quality of life in persons with branch
retinal vein occlusion (BRVO) using the 25-Item NEI Visual Function Questionnaire. Accepted to Brirish Journal of
Ophthalmologt.20l0 Mar 94 (3).
(b)(o
Abstracts / Presentatlons:
Awdeh RM. Digital Management and Education of Cataract Patients: Analyzing Effects of a Mobilc
Health Platform. American Academy of Ophthalmology, Chicago, IL, October 2014.
Awdeh RM. Hanrahan, D, Yoo, S, Katz, J, Donnenfeld, E, Ingrosso M. Digital Management and
Education of Cataract Patients: Analyzing Effects of a Mobile Health Platform. American Society of
Cataract and Refractive Sugcry, Boston, MA, April 2014.
Awdeh RM. Surgical Guidancc Systcm. American Society of Cataract and Refractive Sugery, Boston,
MA, April20l4.
Awdeh RM, Prabhulkar S, de laZerda A, Gambhir S. Development Of Functionalized Gold Nanoparticles
As Diagnostic And Thcrapcutic Agents For Age-Rclated Macular Degeneration. ARVO, Fort Lauderdale,
FL, May 2012.
Matthcws JL, Prabhulkar S, de la Zerda A, Gambhir S, Awdeh RM. Tumors and Non-ncoplastic Lesions:
Expanding Fronticrs from Histology to Molecular Histopathology and Gcne Expression. ARVO, Fort
Lauderdalc, FL, May 2012.
Prabhulkar S, de la Zerda A, Gambhir S, Awdeh RM. Development Of Singlc Step Nano-Optical
Immunoassay As A Replaccment For ELISA For The Measurement of Protein Biomarkers Upregulated in
Disease State. ARVO, Fort Lauderdale, FL, May 2012.
Awdeh RM, de laZerda A, Perez VL, Rugerri M, Gambhir S. Optical Cohercnce Molecular Imaging
Using Gold Nanorods [n Living Mice Eyes. ARVO, Fort Laudcrdale, FL, May 201l.
Awdeh RM, Yoo SH, Culbertson WW. Femtosecond lasers to crcate astigmatic keratotomics. Association
for Research in Vision and Ophthalmology, Surface Ablation, Fcmtolasers, and Crosslinking Conference.
Fort Lauderdale, FL, May 2010.
Awdeh RM, Yoo SH. Confocal microscopy for the detection of acanthamoeba cysts. American Society of Cataract
and Refractive Surgeons. Dimitri Azar Conference. Boston, MA, April 2010.
Lora A, Karp C, Vedula A, Yoo SH, Culbertson WW, Awdeh RM. Post LASIK Peripheral
Inflammatory Keratitis. American Society of Cataract and Refractive Surgeons. Boston, MA, April
2010.
Vedula A, Awdeh RM, Goldman DA. Permancnt Tattoo of a Descemet Stripping Endothelial
Keratoplasty Button. American Society of Cataract and Refractive Surgeons. Boston, MA, April 2010.
11
Rlchard M. Awdeh, t .D.-6
Awdeh RM. Surgical Management of the Mature Cataract. Cataract and Refractive Surgery Congress. Miami, FL,
February 2010.
Awdeh RM. Metallic nbnoparticles as anti-infective agents. International Congress on Ocular Infection. Palm Beach,
FL, February 2010.
Awdeh RM. Ocular Allergy Presentation; Executive Board of ISTA Pharmaceuticats. January 2010.
Awdeh RM. Bascom Palmer Eye Innovations: A Portfolio of Technology for the Future of
Ophthalmology. University of Miam, Innovation Tcchnology Showcase. Miami, FL, November,2009.
Awdeh RM. Dry eye and the patient with cataract. American Society of Ophthalmic Registcred Nurses
Conference. Miami, FL, September 2009.
Awdeh RM, Chang VS, Ide T, Culbertson WW, Yoo SH. Laser in Situ Keratomileusls Using thc VisuMax-MEL80
Platform for Correction of Myopia: Preliminary Report. Amcrican Society of Cornea and Rcfractive Surgeons. San
Francisco, CA, April 2009.
Awdeh RM, Galchus S, Deramo V, Stinnett S, Lee P, Fekrat S. Vision-related quality of life in persons with branch
retinal vein occlusion (BRVO) using the 25-Item NEI Visual Function Questionnaire .. (Paper) Dukc Residents and
Fellows Day, June 200E.
Awdeh RM, Kim TK. Suturelcss Lamellar Keratoplasty: New Tcchnique of Tisseel Glue Application. American
Society of Cornea and Refractive Surgeons. Chicago, IL, April, 2008.
Awdeh RM, Koreishi A, Davies E, Stopa M, Bower B, Izatt JA, Toth C. High-Speed, High-Resolution Spectral
Domain OCT Improves Imaging, Localization, and Quantification of Macular Pathology in AMD. (Paper) Dtke
Residents and Fellows Day, June 2007.
Awdeh RM, Koreishi A, Davies E, Stopa M, Bower B,lzatt JA, Toth C. High-Speed, High-Resolution Spectral
Domain OCT lmproves Imaging, Localization, and Quantification of Macular Pathology in AMD. (Poster)
Association for Research in Vision and Ophthaimology. Fort Lauderdalc, FL. May 8,
200?.
Ahmadi M, Awdeh RM, Adetman, RA. Quality of Life Study Comparing Pneumatic Retinopcxy to Sclcral Buckle
for the Treatrnent of Retinal Detachment. (Update) (Poster) Association for Research in Vision and Ophthalmology.
Fort Lauderdalc, FL. May 10,2007,
Awdeh RM, Carlson AL. Slit Lamp Technique for ihe Rcpositioning of Dislocatcd DSEK Grafts. American
Society of Comea and Refractive Surgeons. San Diego, CA, May 2,2007.
Awdeh RM, Frcedman S, Kim T. A New Trcatment for Corneal Intrastromal Epithelial Cysts. (Paper)
Cornea and Refractive Surgery Congress, Bascom Palmer Eye Institute. Miami, FL. February 9,2007.
Awdeh RM, Davies E, Koreishi A, Stopa M, Bower BA, Izatt JA, Toth CA. Spectral Domain OCT Improves
Imaging and Localization of Macular Pathology in AMD. (Poster) American Academy of Ophthalmology. Las
Vcgas, NV. November 13,2007.. Wlnner: Best Poster.
Awdeh RM' Carlson AL. Verisyse Phakic Refractive IOL: Outcomes and Complications. (Poster) presentod at
the annual meeting of The American Society of Cornea and Refractive Surgeons. San Francisco, CA. May
2005.
Awdeh RM, Carlson AL. Verisyse Phakic Refractive IOL: Outcomes and Complications. @aper) prcscnted at
the annual meeting of The American Society of Comea and Refractivc Surgeons. San Francisco, CA, May
2006.. Wlnner: Paper of Interest.
Awdeh RM, Suncr I. The Role of Peripheral Retinal Nonperfusion in the Progrcssion of Diabetic Eye Disease: An
12
Rlchard M. Awdeh, Iit.D,-7
Evaluation of Ultrawidefield Digital Angiography. (Paper) Duke, University of North Carolina, Wake Forest
Annual Retina Conference. Winston Salem, NC. November 5, 2005.
Awdeh RM, Vedula AS, Membreno JH, Awdeh MM, Adelman RA. A Quality of Life Study Comparing Scleral
Buckle to Pneumatic Retinopexy for the Treatment of Retinal Detachment. (Poster) Association for Rcsearch in
Vision and Ophthalmology. Fort Lauderdale, FL. May 2004.
Awdeh RM, Drewry RD, Kerr NC, Haik BG, Wu S, Xiong X, Merchant TE. Visual Outcomc After 54
Gy Conformal Radiation Therapy in Children with Optic Pathway Glioma. (Poster) Association for
Research in Vision and Ophthalmology, May 2003.
Awdeh RM. Idiopathic Retinal Vascutitis, Aneurysms, and Neuro-retinitis (IRVAN). Doheny Eye
Institute Grand Rounds, University of Southern Califomia, Iune27,2003,
Awdeh RM. A Case of Flat Anterior Chambcr: Aqueous Misdirection on Choroidal Detachment. (Discussant:
Bruce Shields, MD) Connecticut State Glaucoma Society, May 14, 2003.
Awdeh RM. Pathogenesis of Aqueous Misdirection. Yale School of Medicine, Dcpartment of
Ophthalmology, January 25, 2003.
Professlonal Llcensures :
. Diplomate of the American Board of Ophthalmology. Board Certified by the ABO through 2020
. Florida Departmcnt of Health, Medical Board. License to practice medicine in the State of Florida. Drug Enforcement Administration (DEA)
. License to dispense prescription medication. National Provider ldentifier (NPI): 1215198239. New York State, Medical Board. License to practice mcdicine in thc State of Ncw York
Editorial Board Membershlps:
. Cataract and Rcfractive Surgery Today: Current Editorial Board Membcr. Advanced Ocular Carc: Current Editorial Board Membcr
Professlonal Awards:
. Best Doctors, 2011,2012,2013,2014
. Premier Surgcon 250, listing of top 250 ophthalmic surgeons in the United States, 2010. Ophthalmic Innovation Award, Duke Universiry
13
14
Dr. Anthony J. Japour
15
THIS PAGE INTENTIONALLY LEFT BLANK
16
g MIAMIBEACH
NAME: Japour
CITY OF MIAMI BEACH
BOARD AND COMMITTEE APPLICATION FORM
Anthony
Last Name
HOME ADDRESS:
First Name
MlamiBeach
Middle lnitial
FL 33149
Apt No.Home No./Street City State Zip Code
allapour@me.comPHONE
Work
Businegs Name: Anthony Japour & Assoc. Medicat position: Dlrector
Address: 200 Ocean Drlve, 5A Mlami Beach
Fax Email Address
FL 33139
Street City State Zip Code
Pursuant to Clty Code section2-22lal a and b: Members of agencies, boards, ard commiftees shall be affiliated with the city; this
requirement shall be fulfilled in the following ways: a) an individual shall have been a resident of the city for a minimum of six
months; or b) an individual shall demonstrate ornership/interest for a minimum of six months in a business established in the city.
o Resident of Miami Beach for a minimum of six (6) months Yes
r Demonstrate an ownership/interest in a business in Miami Beach for a minimum of six (6) months: Yes
o Are you a registered voter in Miami Beach: Yes
o (Please cirde one): I am nor a resident of South Beach
o I am applying for an appointment because I have special abilities, knowledge and experience. Please list below:
See full resume
o Are you presently a registered lobbyist with the City of Miami Beach? No
Please list y-our Pr_eferencgg in order of Elklng tlllrst Qoicr [2] second choice, and [3] third choice. Please note that only three (3]
cholces wlll be observed by the Clty Clert's Offlca. (Regular Boards of City)
Choice 1: Health Advisory Committee
Ghoice 2: Art in Public Places Committee
Choice 3: Ad Hoc Committee Centennial Celebration
Note: lf applying for Youth AdMsory Board, please indicate your afiiliation with the Scott Rakow Youth Center:
1. Past service on the Youth Center Advisory Board: po years of Service:
2. Present participation in Youth Center activities by your children No if yes, please list the names of your children, their
ages, and which programs. List below:
o Have you ever been convicted of a felony: No lf yes, please explain in detail:
o Do you cunently have a violation(s) of City of Miami Beach codes: No lf yes, please explain in detail:
o Do you cunently owe the City of Miami Beach any money: No lf yes, please explain in detail:
o Are you orrrently serving on any City Boards or Committees: Yes
Health Advlsory
lf yes, whicfr board?
o What organizations in the City of Miami Beach do you cunently hold membership in?
o List all properties owned or have an interest in, which are located within the City of Miami Beach:
o I am now employed by the city of Miami Beach: No Which department?17
belng asked to comply whh federal equa! opportunlty rcportng requiroments.
Gender: Male
Race/Ethnic Categories
What ls your race? Mark one or more races to indicate what you consider yourself to be. White
Other Description:
Are you Spanish/Hispanic/ Latino? Mark the "No" box if not Spanish / Hispanic / Latino. No
PhysicallyChallenged: No
NOTE: lf appolnted, you wlll be required to fottow certaln laws which apply to clty board/commlttee members.
These laws lnclude, but are not llmlted to, the following:
o Prohibition from direcfly or indirectly lobbying city personnel (Miami Beach City Code section 2-459).o Prohibition from contracting with the city (Miami-Dade county code section 2-11 .1).o Prohibition from lobbying before board/committee you have served on for period of one year after leaving office (Miami
Beach Code seciion 2-26).o Requirement to disdose certain linancial interests and gilts (Miami-Dade County Code section 2-1 't.1).
(re: CMB Community DevelopmentAdvisory Committee): prohibition, during tenure and for one yeai after leaving offlrce,
from having any interest in or receiving any benefit from Community Development Block Grant funds for either y-ourcelf,
or those with whom you have business or immediate family ties (CFR 570.611).
Upon request, coples of these laws may be obtained from the City Clerk.
"l hereby attest to the accuracy and truthfutness of the applicatlon and have recaiyed, read and will ablde by Chapter 2, ArlcleVll - of the Clty Code "Standards of Conduc{ for Clty Offtcers, Employees and Agency l/lembers."
I Anthony Japour agreed to the following terms on 1Zt3/.012014 9:2g:30 AM
Reoeived in the City Clerk's Ofiice by:
Name of Deputy Clerk Control No.Date
18
Anthony J. Japour, MJ).
Curriculum Vitae
Anthony Japour & Associates, Medical and Scientific Consulting,Inc.
200 Ocean Drive, #5A
Miami Beach, FL 33139
TeL 305.989.4500
Ernail: ajjapour@me.com
Japour-CY_AUG-2014 P. 1
19
1
2
3
4
5
6
EDUCATION
FULL.TIME ACADEMIC EXPERIENCE
PART.TIME ACADEMIC EXPERIENCE
NON.ACADEMIC EXPERIENCE
EMPLOYMENT RECORDS AT FIU
PUBLICATIONS IN DISCPLINE
Invited Papers in Professional Journals
Peer Reviewed Research Articles
Book Chapters
Abstracts
Other PublicationVBooks
PRESENTED LECTURES AND PAPERS
Invited Lectures
Oral Presentations at Conferences
Poster Presentations at Conferences by Fellows
FUNDED RESEARCH
External Funding as PI
External Funding as Co-PVCo-Investigator
Students/Fellows Funding/Fellowships
PROFESSTONAL HONORS, pRtZES AND FELLOWSHIPS
Local
National
TEACHING
List of courses taught at FIU
MENTORTNG (SCHOLARS & STUDBNTS)
Medical Residents
Postdoctoral Fellows
OTHER PROFESSIONAL ACTIVITIES AND PUBLIC SERVICE
Editorial Boards
Journal Reviews
Grant Reviews
Conference Committees
Conference Committees-AlDS Clinical Trials Group (ACTG)
Others
University Service
3
3
3
4
5
5
5
5
E
I
t6
t6
16
18
18
19
t9
t9
19
20
20
20
20
20
20
20
20
22
22
22
22
22
23
23
23
10
11
t2
Japour_C V_AU G -2014 P. 2
20
University of Chicago Graduate School of
Business, Chicago IL
Harvard Medical School Combined Infecti
Diseases Program (Beth Israel Hospital,
Brigham & Women's Hospital, Dana Farber
Cancer Institute, Boston Children's Hospital),
Boston, MA
Executive Training
Program, Finance
Post-Doctoral
Fellowship in
Infectious Diseases
200t
1989-1992
Mount Auburn Hospital, Cambridge, MA Residency in Internal
Medicine
Mount Auburn Hospital, Cambridge, MA
Queen's Square
london, England
46 Year Elective
Northwestern University Medical School,
Harvard School of Dental Medicine,
Boston MA
l98l-1982
University of Michigan, Ann Arbor, Ml 1977-t981
Harvard Medical School, Boston, MA Internal Medicine/Infectious
Diseases
1995-1996
Harvard Medical School, Boston, MA Internal Medicine/Infectious
Diseases
Jackson North Medical Center
Jackson Health System, Miami FL
Florida International University, Miami, FL
Consultant 20tt-12
Molecular Microbiology & Infectious Diseases,
Herbert Wertheim College of Medicine
Florida International University, Miami, FL
Veteran's Administration Hospital,
Miami, FL
University of Miami, Miami, FL.Voluntary
Associate Professor
Japour_CV_AUG-2014 P. 3
21
Center for Medical Ethics, University of Chicago
Chicago,IL
Visiting Senior
Fe1low
Medical
Ethics
2002-
2003
Medicine, Harvard Medical School,
Boston, MA
Visiting Lecturer Infectious
Diseases
2002-
2003
Rush-Presbyterian St. Lukes' Medical School,
Chicago,IL
Assistant
Professor
Internal
Medicine
2N2-
2003
Harvard Medical School, Boston, MA Assistant
Clinical Professor
Internal
Medicine
t996-
2001
Elite Health Medical Group
Miami Beach, FL
Health & Wellness Physician 2012-Present
Director, Hepatitis C Program
Mount Sinai Medical Center
Miami Beach, FL
Staff Physician 2012-Present
Anthony Japour & Associates, Medical
and Scientific Consulting, Inc.,
Miami Beach, Fl
Managing Director 2006-Present
Research Physicians Network Alliance
Miami Beach, FL
Anthony Japour Medical and Scientific
Consultant, Miami Beach, Fl
Abbott Laboratories, Global Medical
Affairs, Abbott Park, Il
Abbott Laboratories, Abbott Park, Il
Abbott Laboratories, Abbott Park, Il
Abbott Laboratories, Abbott Park, Il
Abbott Laboratories, Abbott Park, Il
Beth Israel Deaconess Medical Center,
Boston, Ma
Principal Investigator
Consultant
Global Director
HM Immunology Franchises
Marketed Product Development,
Global Medical Affairs
Professional Development Director
Physician Rotation Program/
CME Course Director,
Global Medical Affairs
Medical Director
HlV/Transplant Franchise, Medical
Affairs
Associate Medical Director II
Antiviral Venture,
Pharmaceutical Products Division
Associate Medical Director I
Antiviral Venture,
Pharmaceutical Products Division
Senior Associate Physician
20t2-20r3
2002-2006
2001-2002
200t-2002
t999-2001
1998-1999
1996-1998
t995-1996
Japour_CV_AUG-2014 P. 4
22
Beth Israel Deaconess Medical Center,
Boston, Ma
Associate Physician 1992-t994
2003 J. Feinberg, A. Japour. Scientific and Ethical Considerations in Tria1 Design for
Investigational Agents for the Treaftnent of Human Immunodeficiency Virus Infection.
Clinical Infectious Diseases 36: 1-6.
1995 Japour, AJ. The Clinical Significance of HIV-1 Drug Resistance and the Impact on
HIV Pathogenesis. NDS Clinical Care 7(9).
1993 Collier, A., Henry, K., Japour, AJ., van der Horst, C. Switching and Combining
Antiretroviral Therapies - a Roundtable Discussion. NDS Clinical Care 5:3342.
1991 Japour, AJ. and Crumpacker, C.S. Zidovudine Resistance in HIV. dDS Clinical Care
3:65-67.
1987 Japour, AJ. But First, A Little Chi ChL Massachusetts Medicine.
31 2002 S. Walmsley, B. Bernstein, M. King, J. Arribas, G. Beall, p. Ruane, M. Johnson, D.
Johnson, R. Lalonde, A. Japour, S. Brun, E. Sun. Lopinavir-Ritonavir Versus
Nelfinavir for Initial Treatment of HIV Infection. New England Journal of Medicine
346:2O39-2A46.
30 20OZ Benson, C.A., Deeks, S.G., Brun, S.C., Gulick, R.M., Eron, JJ., Kessler, H.A., Murphy,
RI., Hicks, C., King, M., Wheeler, D., Feinberg, J., Stryker, R., Sax, p.E., Riddler, S.,
Thompson, M., Real, K., Hsu, A., Kempf, D., Japour, AJ., Sun, E. Safety and
Antiviral at 48 Weeks of Lopinavir/Ritonavir plus Nevirapine and 2 Nucleoside
Reverse-Transcriptase Inhibitors in Human Immunodeficiency Virus l-Infected Protease
Inhibitor-Experienced. The J o ur nal of I nfe c t io u s D is e ase s I 8 5 : 5 99-607.
2001 Kempf, D.J., Isaacson, J.D., King, M.S., Brun, S.C., Xu, y., Real, K., Bernstein, B.M.,
Japour, AJ., Sun, E., Rode, R.A.Identification of Genotypic Changes in Human
Immunodeficiency Virus Protease that Correlate with Reduced Susceptibility to the
Protease Inhibitor Lopinavir among Viral Isolates from Protease Inhibitor-Experienced
Patients. Journal of Virology 75:7462-7469.
2OOL Murphy, R.L., Brun, S., Hicks, C., Eron, J. J., Gulick, R., King, M., White, A.C.,
Benson, C., Thompson, M., Kessler, H.A., Hammer, S., Bertz, R., Hsu, A., Japour, A.,
Sun, E. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of
antiretroviral-naive adults with HIV-1 infection: 48-week results. NDS I5 l-9.
2000 Gisolf, E.H., Jurriaans, S., Pelgrom, J., van Wanzeele, F., van der Ende, M-E.,
Brinkman, K., Borst, MJ, de Wolf, F., Japour, AJ., Danner, S.A. The Effect of
Treatment Intensification in HlV-Infection: A Study Comparing Treatment with
29
28
27
Japour-CV_AUG-2014 P. 5
23
26
Ritonavir/Saquinavir and Ritonavir/Saquinavir/Stavudine. NDS l4:4O5-4I3.
2000 Welles, S.L., Pitt, J., Colgrove, R., Mclntosh, K., Chung, P.H., Colson, A., Lockman, S.,
Fowler, M. G., Hanson, C., Landesman, S., Moye J., Rich, K.C., Zorrilla, C., Japour, A.
J. HIV-1 Genotype Zidovudine Drug Resistance and the Risk of Maternal-Infant
Transmission In the Women and Infant Transmission Study. NDS 14:263-272.
1999 Colgrove, R., Japour, A. A Combinatorial Ledge: Reverse Transcriptase Fidelity, Total
Body Viral Burden, and the Implications of Multiple-Drug HIV Therapy For the
Evolution of Antiviral Resistance. Antiviral Res 41:45-56.
1999 Cameron, D.W., Japour, AJ., XU, Y., Hsu, A., Mellors, J., Farthing, C., Cohen, C.,
Poretz, D., Markowitz,M.,Follansbee, S., Angel, J.8., McMahon, D., Ho, D.,
Devanarayan,V., Rode, R., Salgo, M.P., Kempf, D.J., Granneman, R., lronard, J.M.,
and Sun, E. Ritonavir and Saquinavir Combination Therapy for the Treatment of HIV
Infection. AIDS 13 :213-224.
1998 Demeter, L.M., D'Aquila, R., Weislow, O., Lorenzo, E., Erice, A., Fitzgibbon, J.,
Shafer, R., Richman, D., Howard, TM., Zhao, Y., Fisher, E., Huang, D., Mayers, D.,
Sylvester, S., Arens, M., Sannerud, K., Rasheed, S., Johnson, V., Kuritzkes, D.,
Reichelderfer, P., Japour, A. Interlaboratory Concordance of DNA Sequence Analysis
To Detect Reverse Transcriptase Mutations In HIV-I Proviral DNA. J. Virol. Methads
75:93-1O4.
1998 Colgrove, R.C., Pitt, J., Chung, P.H., Welles, S.L., Japour, AJ. Selective Vertical
Transmission of HIV-l Antiretroviral Resistance Mutations. NDS 12,2281-2288.
1998 Hsu, A., Granneman, G.R., Cao, G., Carothers, L., Japour, AJ., El-Shourbagy, T.,
Dennis, S., Berg, J., Erdman, K., Leonard, J.M., Sun, E. Pharmacokinetic Interaction
between Ritonavir and Indinavir in Healthy Volunteers. Antimicrob. Agents Chemo.42
2784-279t.
1998 Sham, H., Kempf, D., Molla, A., Marsh, K., Kumar, G., Chen, C., Kati, W., Stewart, K.,
Lal, R., Hsu, A., Betebenner, D., Korneyeva, M., Sudthida, V., McDonald,8., Saldivar,
A., Wideburg, N., Chen, X., Niu, P., Park,nC., Jayanti, V., Grabowski, B., Granneman,
R., Sun, E., Japour, A., Leonard, J., Plattner, J., Norbeck, D. ABT-378, a Highly Potent
Inhibitor of the Human Immunodeficiency Virus Protease. Antimicrob. Agents Chemo.
42:3218-3224.
1998 Fiscus, S.A., Hughes, M.D., Lathey, J.L., Pi, T., Jackson,8.J., Rasheed, S., Elbeik, T.,
Reichman, R., Japour, AJ., Byington, R., Scott, W., Griffith, 8.p., Katzenstein, D.A.,
Hatnmer, S.M. Changes in Virologic Markers as Predictors of CD4 Cell Decline and
Progression of Disease in Human Immunodeficiency Virus Type l-Infected Adults
Treated with Nucleosides. J. Infect. Dis.l77:625-633.
1998 Kew, Y., Olsen, LR., Japour, AJ., Prasad, V.R. Insertions into the p3-Ba Hairpin
Loop of HIV-I Reverse Transcriptase Reveal a Role for Fingers Subdomain in
Processive Polymerization. "/. Biol. C hem. 27 3:7 529-7 537 .
1998 Lathey, J.L., Hughes, M.D., Fiscus, S.A., Pi, T., Jackson, J.B., Rasheed, S., Elbeik, T.,
Reichman, R., Japour, AJ., D'AquiIa, R.T., Scott, W., Griffith, B.p., Hammer, S.M.,
Katzenstein, D.A. Variability and Prognostic Values of Virologic and CD4 Cell
Measures in Human lmmunodeficiency Virus Type l-Infected Patients with 200-500
CD4 Cells/mm' 1e.CtC 175). J. Infect. Dis. t77:617-24.
1998 Kempf, DJ., Rode, R.A., Xu, Y., Sun, E., Heath-Ch\ozzi,M.E., Valdes, J., Japour,
AJ., Danner, S., Boucher, C., Molla, A., Leonard, J.M. The Duration of Viral
Suppression During Protease Inhibitor Therapy for HIV-I Infection is Predicted by
Plasma HIV-I RNA at the Nadir. AIDS t2:F9-F14.
1997 Race, E., Adelson-Mitty, J., Barlam, T., Japour, AJ. Focal Inflammatory
Lymphadenitis (FIL) and Fever Following Initiation of Protease Inhibitor (PRI) in
25
24
23
22
2t
20
t9
16
18
t7
15
Japour_CV_AU G -2014 P. 6
24
I4
13
t2
ll
l0
Patients with Advanced HIV-I Disease. Lancet 351:252-255.
1997 Marschner, I.C., Mayers, DI., Erice, A., Smeaton, L., Johnson, V.A., Richman, D.D.,
Reichelderfer, P., Japour, AJ. Standardized Peripheral Blood Mononuclear Cell
Culture Assay forZidovudine Susceptibility Testing of Clinical Human
Immunodeficiency Virus Type I Isolates: Effect of Reducing the Numbers of
Replicates and Concentrations. J . C lin. Microbiol. 35 :7 56-7 58.
1996 Katzenstein, D.A., Hammer, S.M., Hughes, M., Gundacker, H., Jackson, J,B., Fiscus, J.,
Rasheed, S., Elbeik, T., Reichman, R., Japour, AJ., Merigan, T.C., Hirsch, M. The
Relation of Virologic and Immunologic Markers to Clinical Outcomes After Nucleoside
Therapy in HlV-Infected Adults With 200 to 50O CD4 Cells Per Cubic Millimeter. New
England J . Med. 335:lO9 1-1098.
1996 Shafer, R.W., Winters, M.A., Mayers, D., Japour, AJ., Kuritzkes, D., Weislow, O.,
White, F., Erice, A., Sannerud, K., Iversen, A., Pena, F., Dimitrov, D., Frenkel, S.,
Reichelderfer, P.S. Inter-Laboratory Comparison of Sequence-Specific PCR and Ligase
Detection Reaction to Detect an HIV-I Drug Resistance Mutation. J. Clin. Microbiol.
34:1849-1853.
1996 Coombs, R.W., Welles, S.L., Hooper, C., Reichelderfer, P.S., D'Aquila, R.T., Japour,
AJ., Johnson, V.A., Kuritzkes, D.R., Richman, D.D., Kwok, S., Todd, J., Jackson, J.B.,
DeGruttola, V., Crumpacker, C.S., and Kahn, J. Association of plasma Human
Immunodeficiency Virus Type-l RNA Level With Risk of Clinical Progression in
Patients With Advanced Infection. J . Infect . Dis . 17 4:704-7 lZ.
1996 Japour, AJ., Lertora, JJ., Meehan, P.M., Erice, A., Connor, J.D., Griffith, B.p., Clax,
P.A., Holden-Wiltse, J., Hussey, S., Walesky, M., Cooney, E., Pollard, R., Timpone, J.,
Mclaren, C., Johanneson, N., Wood, K., Booth, D.K., Bassiakos, Y., Crumpacker, C.S.,
for the AIDS Clinical Trials Group 231 Protocol Team. A Phase I Study of the Safety,
Pharmacokinetics, and Antiviral Activity of Combination Didanosine and Ribavirin. J.
Acquired Immune Defic . Syndromes Hum. Retrovirol. 13:235-246.
1995 Japour, AJ., Welles, S., D'Aquila, R.T., Johnson, V.A., Richman, D.D., Coombs,
R.W., Reichelderfer, P.S., Kahn, J., DeGruttola, V., Crumpacker, C.S., Kuritzkes, D.R.
Prevalence and Clinical Significance of Zidovudine (ZDV) Resistance Mutations in
Human Immunodeficiency Virus Isolated from Patients Following Long-Term
Zidovudine Treatment. J . Infect. Dis . 17 l:1172-1179 .
1995 Welles, S., Jackson, J., Yen-Lieberman, B., Demeter, L., Japour, AJ., Smeaton, L.M.,
Johnson, V., Kuritzkes, D., D'Aquila, R., Reichelderfer, P., Richman, D., Reichman, R.,
Fischl, M., Dolin, R., Coombs, R., Kahn, Mclaren, C., Todd, J., Kwok, S., and
Crumpacker, C. Prognostic Value of Plasma HIV-I RNA Levels in Patients with
Advanced HIV- 1 Disease and With Little or No Zidovudine Therapy . J . Infect. Dis .
174:696-7O3.
lgg5 D'Aquila, R.T., Johnson, V.A., Welles, S.L., Japour, AJ., Kuritzkes, D., DeGruttola,
V., Reichelderfer, P.S., Coombs, R.W., Crumpacker, C., Kahn, J.O., Richman, D.D.
Zidovudine Resistance and Human Immunodeficiency Virus Type I Disease
Progression During Antiretroviral Therapy. Annals Internal Med.122:4O1-408.
1995 Lan, Y., Japour, AJ., Kim, S., Welles, SI., Crumpacker, C.S., Cooper, E., Al-Attar, L,
Mclntosh, K. A Rapid, Direct Test for Zidovudine Susceptibility in Clinical Isolates of
Human Immunodeficiency Virus Type I (HIV-1) From Infected Children. Clinic. Diag.
Virol.3:259-27l.
1994 Mayers, D.L., Japour, AJ., Arduino, J.M., Hammer, SM., Reichman, R., Wagner,
K.F., Chung, R., Lane, J., Crumpacker, C.S., Mcleod, G.X., Beckett, L.A., Roberts,
C.R., Winslow, D., Burke, D. and the RV43 Study Group. Dideoxynucleoside
Resistance Emerges with Prolonged Zidovudine Monotherapy. Antimicrob. Agents
Japour_CV_ AU G -2014 P. 7
25
Chemo.38:307-314..
1994 Japour, AJ., Fiscus, S.A., Arduino, J.M., Mayers, D.L., Reichelderfer, P.S., Kuritzkes,
D.R. Standardized Microtiter Assay for Determination of Syncytium-Inducing
Phenotypes of Clinical Human Immunodeficiency Virus Type I Isolates. J. Clinic.
Mi cr o bi o I . 32:229 | -229 4 .
lgg3 Japour, AJ., Mayers, D.L., Johnson, V.A., Kuritzkes, D.R., Beckett, L.A., Arduino,
JJVL, Lane, J., Black, RJ., Reichelderfer, P.S., D,Aquila, R.T., Crumpacker, C.S. The
RV-43 Study Group, The AIDS Clinical Trials Group Virology Committee Resistance
Working Group. A Standardized Peripheral Blood Mononuclear Cell Culture Assay for
the Determination of Drug Susceptiblities of Clinical Human Immunodeficiency Virus-l
(HIV- I ) Isolates. Antimicrob. Agents Chemo. 37: 1095- I l0l.
1991 AJ. Japour, P.A. Chatis, H.A. Eigenrauch, C.S. Crumpacker. Detection of Human
Immunodeficiency Virus Type 1 Clinical Isolates With Reduced Sensitivity to
Zidovudine and Dideoxyinosine by RNA-RNA Hybridization. PNAS 88:3092-3096.
1983 Keith, D.A., Gundberg, CM., Japour, AJ., Arnoff, J., Alverez, N., Gallop, p.M.
Vitamin K Dependent Proteins and Anticonvulsant Medications. Clinic- Pharm.Therap.
34:529-32.
2007 AJ. Japour. lnformed Consent, Ethical Issues in Performing HIV Research.
Fundamentals of HIV Medicine. Ameican Association of HIV Medicine. Washington
DC,54.2:722-724.
2OO7 AJ. Japour. Ethical Conduct of Clinical Trials, IRBs, and Financial Conflicts of
Interest, Ethical lssues in Performing HIV Research. Fundamentals of HIV Medicine.
American Association of HIV Medicine, Washington DC 54 .t:i 17 -721 .
LggT AJ. Japour. Management of CMV Disease. In Cotton DJ & Watts DH (eds): Medical
Management of AIDS in Women,New York: John Wiley & Sons,Inc.
1997 A. Molla, AJ. Japour. HIV Protease Inhibitors . Current Opinion in Infectious Diseases
lO:491-495.
Ptr!_ltg_U9_{ |t 4$ggiution l 3 5 ft Annual Meetin g.
2W6 Gulnik S., AfoninaE., Eissenstat M., Parkin N., JapourA., and Erickson J. SpI-256, a
Highly Potent HIV Protease Inhibitor with Broad Activity against MDR Strains. 13'h
Conference on Retroviruses and Opportunistic Infections, Denver, Colorado, February
5-8.
2OO2 i Cameron, D., Angel, J., Ryan, J., Jiang, P., Rode, R., Farthing, C., Cohen, C., Mellors,
J.,Poretz, D., Markowitz, M., Ho, D., McMahon, D., Drennan, D., Seidler, T., Sun, E.,
Japour, AJ. Durability of Ritonavir (RTV) Saquinavir (SQV) Dual Protease Inhibitor
Therapy in HIV infection: 5-Year Follow-up.Eh cRoI February 24-2g,seattle, wA.
Japour-CY_AUG-2014 P. E
26
81
80
79
78
75
74
73
77
76
Ritonavir plus Saquinavir (SQV) Therapy in an HlV-Infected Cohort. g'h CROI
February 24-28,Seattle, WA.
2002 Steinberg, S., Venuto, R., Kuruvila, K., Taylor, D., Anil Kumar, M., First, M., Greco,
R., Boodhoo, T., Singh, A., Ashraf, T., Japour, A., Ryan, J. A Randomized, Open-label
Preference Study of GengraP Compared to Neoral@ in Stable Solid-organ Transplant
Recipients., T'h International Society of Pharmacoeconomics and Outcomes Research -
ISPOR, Arlington, May 19-21. Published in Value in Health 6(3), 198-290.
2OOl Harley, W., DeJesus, E., Pistole, M., Sension, M., Garrett, L., Nettler, S., Jiang, p.,
Rode, R., Ashraf, T., McMillan, F., Japour, A. A 24-Week Randomized, Controlled,
Open-Label Evaluation of Adherence and Convenience of Continuing Indinavir Versus
Switching to Ritonavir/Indinavir 4AO mgl400 mg BID (The NICE Study). 8'h Conference
on Retroviruses and Opponunistic Infections, Chicago, Illinois, February 4-8.
2OO2 Hsu, A., Zolopa, A., Shulman, N., Havlir, D., Gallant, J., Race, E., Jiang, p., Boller, S.,
Swerdlow, J., Jasinsky, O., Renz, C., Japour, A., Kempf, D., Sun, E. Final Analysis of
Ritonavir (RTV) Intensification in Indinavir (IDV) Recipients with Detectable HIV
RNA Levels. 8'h Conference on Retroviruses and Opportunistic Infections, Chicago,
Illinois, February 4-8.
2001 Cohen, C., Ryan, J., Jiang, P., Cameron, D.W., Mellors, J., Kakuda, T., Japour, AJ.
Effect of Nucleoside Intensification on Prevalence of Morphologic Abnormalities at
Year 4 of Ritonavir + Saquinavir Therapy in an HlV-Infected Cohort. 1" IAS
Conference on HIV Pathogenesis and Treatment, Buenos Aires, July 7.
2OOl Farthing, C., Ryan, J., Rode, R., Markowitz,M.,Cameron, D.W., McMahon, D.,
Japour, AJ. Durability of Ritonavir + Saquinavir Dual Protease Inhibitor Therapy in
HIV Infection: Four-Year Follow-Up. 1" IAS Conference on HIV Pathogenesis and
Treatment, Buenos Aires, July 7.
2OOl King, M., Brun, S., Marsh, T., Real, K., Kempf, D., Japour, A., Sun, E. Factors
Affecting Long-Term Virologic Suppression in Phase II Studies of Lopinavir/ritonavir
(LPV/r) in ARV-Naive or Pl-Experienced Patients. 1" IAS Conference on HIV
Pathogenesis and Treatment, Buenos Aires, July 7.
2001 Sension, M., Harley, W., DeJesus,8., Jiang, P., Garrett, L., McMillan, F., Clax, p.,
Japour, A. Final Analysis of a24-week Randomized, controlled, open-Label
Evaluation of Adherence and Convenience of Continuing Indinavir vs. Switching to
Ritonavir/Indinavir 400 mg/400 mg BID. 1" IAS Conference on HIV Pathogenesis and
Treatment, Buenos Aires, July 7.
2001 Hicks, C., Brun, S., King, M., Marsh, T., Deeks, S., Benson, C., Gulick, R., Kessler, H.,
Murphy, R., Wheeler, D., Feinberg, J., Eron, J., Sax, p., Stryker, R., Riddler, S.,
Thompson, M., Richards, B., Kempf, D., Japour, A., Sun, E. for the Mr97-765 Study.
Kaletra (Lopinavir/Ritonavir) Therapy in Single Protease Inhibitor Experienced
Patients: 144 Week Follow Up. 8'n European Conference on Clinical Aspects and
Treatment of HlV-Infection, Athens, October 28-31.
2001 Perrin, L., King, M., Brun, S., Yerly, S., Marsh, T., Travers, N., Real, K., Japour, A.,
Sun, E. Failure to Achieve HIV RNA < 3 Copies/ml Does Not Predict Loss of
Virologic Response to Kaletra (Lopinavir/Ritonavir) Therapy through 3 Years.4l"
Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago,
December l6-19.
2001 Piliero, PJ., Preston, S.L., Japour, AJ., Stevens, R.C., Morvillo, C., Drusano, G.L.
Pharmacokinetics (Pk) of the Combination of Ritonavir (RTV) Plus Saquinavir (SeV),
with and without Efavirenz (EFV), in Health Volunteers.4l"tlnterscience Conference
on Antimicrobial Agents and Chemotherapy, Chicago, December l6-19.
2000 Coplan, P., Cormier, K., Japour, A., Mardit-Kremers, H., Nikas, A., Lewis, R., Xu, y.
72
7t
Japour_CV_AUG-2014 P. 9
27
70 2000
69 2000
68 2000
67 2000
66 2000
65 2000
64 2000
63 2000
62 2000
Myocardial Infarction Incidence in Clinical Trail of 4 Protease Inhibitors. 7'h Conference
on Retroviruses and Opportunistic Infections, January 30-Febuary 2.
Gulick, R., King, M., Brun, S., Real, K., Murphy, R., Hick, C., Eron, J., Thommes, J.,
Thompson, M., White, C., Benson, C., Albrecht, M., Kessler, H., Hsu, A., Bertz, R.,
Kempf, D., Sun, E., Japour, A. ABT-378/Ritonavir (ABT-378ir) in Antiretroviral-
Naive HI+ Patients 72 Weeks. T'h Conference on Retroviruses and Opportunistic
Infections, January 30-Febuary 2.
Gisolf, E. H., Jurriaans, S., Pelgrom, J., Van Wanzeele, F., Van Der Ende, M. E.,
Brinkman, K., Borst, M. J., De Wolf, F., Sun, E., Japour, A., Danner, S. A.
Ritonavir/Saquinavir Versus Ritonavir/Saquinavir/Stavudine in HIV-l-Infected
Individuals During 48 Weeks: The Effect of treatment Intensifications. 7'h Conference
on Retroviruses and Opportunistic Infections, January 3O-Febuary 2.
Deeks, S., Brun, S., XU, Y., Real, K., Benson, C., Kessler, H., Murphy, R., Wheeler, D.,
Hicks, C., Eron, 8., Feinberg, J., Gulick, R., Sax, P., Stryker, R., Riddler, S., Thompson,
M., King, M., Potthoff, A., Hsu, A.,Bertz,R., Molla, A., Mo, H., Kempf, D., Japour,
A., Sun, E. ABT-378/Ritonavir (ABT-378/r) Suppresses HIV RNA to <400 copies/ml
in 84Vo of Pl-Experienced Patients at 48 Weeks. 7'h Conference on Retroviruses and
Opportunistic Infections, January 30-Febuary 2.
Cameron, D.W., Xu, Y., Rode, R., Cohen, C., Mellors, J., Farthing, C., poretz, D.,
Markowitz, M., Ho, D., McMahon, D., Drennan, D., Hill, L., Sun, E., Japour, A. Three-
Year Follow-Up and Conditional Outcomes Survival Analysis of Ritonavir (RTV) plus
Saquinavir (sQV) Therapy in HIV Infection. 7'h conference on Retroviruses and
Opportunistic Infections, January 30-Febuary 2.
Shulman, N., Zolopa, A., Havlir, D., Gallant, J., Race, E., Lam, W., Hill, L., Japour, A.,
Kempf, D., Sun, E., Hsu, A. Ritonavir Intensification in Indinavir Recipients with
Detectable HIV RNA Levels. 7'h conference on Retroviruses and opportunistic
Infections, January 30-Febuary 2.
Pitt, J., Colgrove, R., Thompson, 8., Japour, A., Welles, S. Association of Maternal
ZDV Use during Pregnancy and Infant ZDV Genotypic Resistance with Rapid Disease
Progression among Infants in the wITS. 7'h conference on Retroviruses and
Opportunistic Infections, January 30-Febuary 2.
Kempf, D., Xu, Y., Brun, S., King, M., Mo, H., Real, K., Bernstein, B., Hertogs, K.,
Larder, B., Molla, A., Japour, A., Sun, E. Baseline Genotype phenotype Do Not
Predict Response to ABT-378/Ritonavir in Pl-Experienced Patients at24 and48 Weeks.
7'h Conference on Retroviruses and Opportunistic Infections, January 30-Febuary 2.
Molla, A., Brun, S., Mo, H., Real, K., Poddig, J., Bernstein, B., Hertogs, K., Larder, B.,
Lie, Y., Hellmann, N., Vasavanonda, S., Chernyavskiy, T., Freimuth, W., Japour, A.,
Sun, 8., Kempf, D. Genotypic and Phenotypic Analysis of Viral Isolates from Subjects
with Detectable viral Load on Therapy with ABT-378/Ritonavir (ABT-378 h).4'h
International Workshop on HIV Drug Resistance Focuses on New Anti-HIV Drugs
Sitges, Portugal, June 12-16.
Kempf, D., Isaacson, J., King, M., Brun, S., Xu, Y., Real, K., Lie, y., Hellmann, N.,
Hertogs, K., Larder, B., Bernstein,8., Japour, A., Sun,8., Rode, R. Genotypic
Correlates of Reduced In Vitro Susceptibility to ABT-378 in HIV [solates From patients
Failing Protease Inhibitor Therapy. 4'h International Workshop on HIV Drug Resistance
Focuses on New Anti-HIV Drugs, Sitges, Portugal, June l2-16.
Kessler, H., Brun, S., King, M., Marsh, T., Murphy, R., Eron, J., Gulick, R., Glesby, M.,
Hicks, C., Benson, C., Thompson, M., Thommes, J., Deeks, S., Wheeler, D._White, C.,
Stryker, R., Feinberg, J., Albrecht, A., Sax, P., Riddler, S., Real, K., Xu, y., Japour, A.,
Sun, E. Analysis of Safety Data from ABT-378/ritonavir (ABT-378/r) in Two Phase II
61 2000
Japour_CV_AUG-20f4 P. f0
28
60 2000
s9 2000
58 2000
57 2000
56 2000
55 2000
54 2000
53 2000
52 2000
5l 2000
Clinical Trials XIII International AIDS Conference, July 9-14.
Thompson, M., Brun, S., Xu, X., Murphy, R., Eron, J., Gulick, R., Glesby, M., Hicks,
C., Benson, C., Thommes, J., Kessler, H., Deeks, S., Wheeler, D., White, C., Stryker, R.,
Feinberg, J., Albrecht, M., Sax, P., Riddler, S., Real, K., King, M., Japour, A., Sun, E.,
Analysis of Duration of Virologic Response in Two Phase II Studies of ABT-
378/ritonavir (ABT-3781r) at72 Weeks. XI[[ International AIDS Conference, July 9-14.
Thompson, M., Murphy, R., Gulick, R., Hicks, C., Eron, J., Benson, C., Thommes, J.,
Kessler, H., Deeks, S., Wheeler, D., White, C., Stryker, R., Feinberg, J., Albrecht, M.,
Sax, P., Riddler, S., Real, K., King, M., Japour, A., Sun, 8., Analysis of Duration of
Virologic Response in Two Phase II Studies of ABT-378/ritonavir (ABT-378/r) at72
Weeks. XIII International AIDS Conference, July 9-14.
DeJesus,8., Pistole, M., Fetchick, R., Lauermann, M., Roland, R., Garrett, L., Jiang, p.,
McMillan, F., Japour, A. A Randomized, Controlled, Open-Label Study Comparing the
Adherence and Convenience of Continuing Indinavir QSH vs. Switching to
Norvirilndinavir 400 mgl4oo mg BID (The NICE study). XIII International AIDS
Conference, July 9-14.
Hsu, A., Williams, L., Chiu, Y-L., Hill, L., McMillan, F., Lamm, J., Rynkiewicz,K.,
Foit, C., Ji, Q., Hutman, W., Ryan, J., Sun, E., Japour, A. Pharmacokinetic (PK)
Interactions Between Ritonavir (RTV) and Amprenavir (APV) in Healthy Volunteers.
XIII International AIDS Conference, July 9-14.
Havlir, D., Gallant, J., Race, E., Lam, W., Schulman, N., Zolopa,A., Ryan, J., Japour,
A., Kempf, D., Sun, E. Ritonavir Intensification in lndinavir Recipients: Tolerance,
Antiviral Effect and Pharmacokinetics. XIII International AIDS Conference, July 9-14.
Williams, L., O'Dea, R., Weinberg, M., Keene, M., Japour, A., Centko, M., Bachand,
J., Hsu, A., Hill, L., Lamm, J. High Incidence of Rash Associated with Amprenavir
(APV) During a Pharmacokinetic (PK) Interaction Trial in HlV-Negative, Healthy
Volunteer. XIII International AIDS Conference, July 9-14.
Benson, C., King, M., Marsh, T., Murphy, R., Hicks, C., Thommes, J., Gulick, M,
Thompson, M., White, C., Albrecht, M., Kessler, H., Hsu, A.,Bertz, R., Kempf, D.,
Travers, N., Real, K., Japour, A., Sun, E. ABT-378/ritonavir (ABT-378/r) in
Antiretroviral-naive HIV+ Patients: 96 weeks.40'h ICAAC conference, Toronto,
Canada, September l7 -2O.
Brun, S., Kempf, D., Molla, A., Mo, H., Xu, Y., Real, K., Poddig, J., Hertogs, K.l,
Larder, B., Freimuth, W., Japour, A., Sun, E. Analysis of Viral Isolares Following Viral
Load Rebound on Therapy with ABT-378/ritonavir (ABT-378/r).40th ICAAC
Conference, Toronto, Canada, September 17 -2O.
Feinberg, J., Brun, S., Marsh, T., Benson, C., Deeks, S., Kessler, H., Murphy, R.,
Gulick, R., Wheeler, D., Hicks, C., Eron, J., Sax, P., Stryker, R., Riddler, S., Thompson,
M., Real, K., Hsu, A.,Bertz,R., Kempf, D., Japour, A., Sun, E. Durable Suppression of
HIV+ RNA After Two Years of Kaletra (ABT-378/ritonavir) Therapy in Single Protease
Inhibitor Experienced Patients.40'h ICAAC conference, Toronto, canada, September
t7-20.
Stryker, R., Brun, S., King, M., Marsh, T., Mulphy, R., Hicks, C., Eron, J., Thommes, J.,
Gulick, R., Glesby, M., Thompson, M., White, C., Benson, C., Albrecht, M., Kessler,
H., Real, K., Japour, A., Perrin, L., Sun, E. Kaletra (ABT-378/ritonavir) in Anti-
retroviral-Narve HIV+ Patients: Follow-up Beyond Two Years and viral Load
Suspension Below 3 Copies/ml.40'h ICAAC conference, Toronto, canada, September
t7-20.
Benson, C., Brun, S., King, M., Real, K., Murphy, R., Hicks, C., Eron, J., Thommes, J.,
Gulick, R., Glesby, M., Thompson, M., White, C., Albrecht, M., Kessler, H., poddig, J.,
50 2000
Japour_CV_AUG-2014 P. 1l
29
49
48
47
46
45
44
4t
43
42
Sun, 8., Japour, A. Two Year Follow-Up of ABT-37S/Rironavir (ABT-378 in
Antiretroviral Narve HIV + Patients.40'h ICAAC Conference, Toronto, Canada,
September l7-20.
2000 Bertz, R., Lam, W., Rynkiewicz,C.,Foit,I., Benedek, W., Fiske, p., Bryan, p., Sylte, J.,
Brun, S., Japour, A., Granneman, G.R., Sun, E. Assessment of the Pharmacokinetic
Interaction Between ABT-37S/ritonavir (ABT-378/r) and Efavirenz (EFV) in Healthy
volunteers and in HIV + subjects.40'h ICAAC conference, Toronto, canada,
September l7-20.
2000 Feinberg, J., Brun, S. Marsh, T., King, M., Benson, C., Deeks, S., Kessler, H., Murphy,
R., Gulick, R., Wheeler, D., Hicks, C., Eron, J., Sax, P., Stryker, R., Riddler, S.,
Thompson, M., Real, K., Hsu, A.,Bertz,R., Kempf, D., Japour, A., Sun, E. Durable
suppression of HIV + RNA After Two Years of Kaletra (ABT-378/ritonavir) Therapy in
Single Protease Inhibitor Experienced Patients.5'h International Congress on Drug
Therapy in HIV Infection, Glasgow, UK, October 22-26.
2000 Stryker, R., Brun, S., King, M., Marsh, T., Murphy, R., Hicks, C., Eron, J., Thommes, J.,
Gulick, R., Glesby, M., Thompson, M., White, C., Benson, C., Albrecht, M., Kessler,
H., Real, K., Japour, A., Perrin, L., Sun, E. Kaletra (ABT-378/ritonavir) in
Antiretroviral-Naive HIV + Patients: Follow-up Beyond Two Years and Viral Load
Suppression Below 3 Copies/ml.5'h International Congress on Drug Therapy in HIV
Infection, Glasgow, UK, October 22-26.
2000 Cohen, C., Cameron, D., Xu, Y., Rode, R., Mellors, J., Farthing, C., poretz, D.,
Markowitz, D., Ho, D., McMahon, D., Drennan, D., Selness, K., Ryan, J., Sun, E.,
Japour, AJ. Effect of NRTI Intensification on Prevalence of Body Composition
Abnormalities at Week 144 of Ritonavir + Saquinavir Therapy in an HlV-Infected
Cohort. 2nd International Workshop on Adverse Drug Reactions and Lipdystrophy in
HIV Toronto, CA, September 13-15.
1999 Murphy, R., King, M., Brun, S., Orth, K., Hicks, C., Eron, J., Thommes, J., Gulick, R.,
Thompson, M., White, C., Benson, C., Hammer, S., Kessler ,H.,Bertz,R., Hsu, A.,
Kempf, D., Sun, E., Japour, A. ABT-378/ritonavir Therapy in Antiretroviral-Naive
HIV-I Infected Patients for 24 weeks. 6'h Conference on Retroviruses and Opportunistic
lnfections, January 3 1 - February 4.
1999 Mo, H., Chernyavskiy, T., Lu, L., Staser, J., Cohen, C., Cameron, W., Markowitz,M.,
Xu, Y., Kohlbrenner, W., Sun, E., Kempf, D., Japour, A., Molla, A. Characterization of
HIV-1 in Patients Following Long Term RTV-sev rherapy.6'h conference on
Retroviruses and Opportunistic Infections, January 3l - February 4.
1999 colgrove, R., Pitt, J., Japour, A., welles, s. Evolutionary Hotspot Around RT codon
215 Evolves During Zidovudine Exposure. 6'h Conference on Retroviruses and
Opportunistic Infections, January 31 - February 4.
1999 Hsu, A., Granneman, R., Xu, Y., Rode, R., Japour, A., Leonard, J., Sun, E.Initial HIV
Clearance Rates Do Not Predict Long-Term Antiviral Activity for Ritonavir-Saquinavir
(R-S) Combination Therapy in HlV-Protease Inhibitor-Naive Patient. 6'h Conference on
Retroviruses and Opportunistic Infections, January 3l - February 4.
1999 Bertz,R., Lam, W., Brun, S., Kumar, G., Fields, C., Orth, K., Jennings, J., Hsu, A.,
Granneman, R., Japour, A., Sun, E. Multiple-Dose Pharmacokinetics (pK) of ABT-
378/Ritonavir (ABT-378/r) in HIV+ Subjects.3gth ICAAC Conference on Antimicrobial
Agents and Chemotherapy, September 26-29.
1999 Hsu, A., Lal, R., Bertz, R., Lam, W., Jennings, J., Brooks, R., Bryan, p., Granneman, R.,
Sun, E., Japour, A. ABT-378 and Ritonavir Exposures Are Not predicted by
Erythromycin Breath Test (ERMBT). 39'h ICAAC Conference on Antimicrobial Agents
and Chemotherapy, September 26-29.
40
Japour-CV_ AUG-2014 P. 12
30
37
36
39
38
35
34
33
29
1999 Hicks, C., King, M., Brun, S., Real, K., Murphy, R., Eron, J., Thommes, J., Gulick, R.,
Glesby, M., Thompson, M., White, C., Benson, M., Albrecht, M., Kessler, H., Hsu, A.
Bertz, R., Kempf, D., Japour, A., & Sun, E. ABT-378/Ritonavir (ABT-37g/R) in
Antiretroviral Naive HIV + Patients: 48 Weeks. Tth European Conference on Clinical
Aspects and rreatment of HIV Infection. Lisbon, Portugal, october 23-27 .
1999 Lal, R., Bertz, R., Lam, W., Jennings, J., Brooks, R., Bryan, p., Sun, E., Granneman,
G.R., & Japour, A. Evaluation of the Pharmacokinetics (PK) of the Concurrent
Administration of ABT-378/Ritonavir (ABT-378/R) and Nevirapine (NVP). 7th
European Conference on Clinical Aspects and Treatment of HIV lnfection. Lisbon,
Portugal, October 23-27 .
1998 Lal, R., Hsu, A., Granneman, G.R., El-Shourbagy, T., Johnson, M., Lam, W., Manning,
L., Japour, AJ., Sun, E. Abbon Laboratories,Illinois "Multiple Dose Safety,
Tolerability and Pharmacokinetics of ABT-378 in Combination with Ritonavir." 5th
Conference on Retroviruses and Opportunistic Infections. Chicago,Illinois, February.
1998 Colgrove, R., Pitt, J., Chung, P., Welles, S., Japour, AJ., Harvard Medical School,
Boston, Massachusetts, columbia University, and University of Minnesota,
Minneapolis, Minnesota. Selective Vertical Transmission of HIV-l Zidovudine
Resistance Mutations. 5'h Conference on Retroviruses and Opportunistic Infections,
Chicago, Illinois.
1998 Mellors, J., Japour, AJ., Cameron, W., Cohen, C., Farthing, C., Follansbee, S.,
Markowitz, M., Poretz, D., Ho, D., McMahon, D., Xu, y., Rode, R., Hsu, A., Velo, C.,
Berg, J., Salgo, M., Leonard, J., Sun, E. Sustained Activity of Ritonavir (RTV)
Saquinavir (SQV) in Protease Inhibitor-Naive Patients After 72 Weeks. 5'h Conference
on Retroviruses and Opportunistic Infections, Chicago, Illinois.
1998 Cameron, D.W., Japour, AJ., Mellors, C., Farthing, C., Cohen, C., Markowitz,M.,
Poretz, D., Follansbee, D., Ho, D., McMahon, D., Berg, J., Nieves, J., Xu, y., Rode, R.,
Salgo, M., Leonard, J., Sun, E. Antiretroviral Safety & Durability of Ritonavir (RIT)-
Saquinavir (SQV) in Protease Inhibitor-Naive Patients in Year Two of Follow-up.5'h
Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, February.
1998 Japour, AJ., Kempf, D., Mo, H., Chernyavskiy, T., Kohlbrenner, W., Sun, E., Molla,
A. HIV Protease Mutations Following Ritonavir-Saquinavir Therapy and Long-Term
Outcome on Plasma Viral Load Following an Intensification Strategy.2'd International
Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore,Italy,
June24-27.
1998 Hsu, A., Granneman, R., Molla, A., Vasavanonda, S., Japour, A., Kempf, D., Sun, E.
Ritonavir-Containing Dual Protease Inhibitor Regimens May Have Synergistic Antiviral
Effects in Patients - Base on In Vitro Model. l2'h World AIDS Conference, Geneva,
Switzerland, June 28 - July 3.
1998 Mellors, J., Japour, A., Leonard, J., Sun, E., Xu, y., Salgo, M.,M97-462 Study Groups.
Ritonavir (RTV)-Saquinavir (SQV) in Protease Inhibitor-Narve Patients after 72Weeks.
12'h World AIDS Conference, Geneva, Switzerland, June 28 - July 3.
1998 Gisolf, E.H., De Wolf, F., Pelgrom, J., Van Wanzeele, F., popescu, M., Japour, A.,
Danner, S.A., van Leeuwen, R. Treatment of Ritonavir (RTV)/Saquinavir (sev)
Versus RTV/SQV/Stavudine (d4T) (The Prometheus Study): Preliminary Results. l2'h
World AIDS Conference, Geneva, Switzerland, June 28 - July 3.
1997 Race, E., Adelson-Mitty, J., Barlam, T., and Japour, AJ. Focal Inflammatory
Lymphadenitis (FIL) and Fever Following Initiation of Protease Inhibitor (PRI) in
Patients with Advanced HIV-l Disease. 4'h Conference on Retroviruses and
Opportunistic Infections, Washington, DC. 352.
1997 Colgrove, R., Japour, AJ. Mathematical Modeling of Within-Patienr Evolution of
32
31
30
28
Japour_CV_AUG-2014 P. 13
31
27
26
25
HIV-1 Antiretroviral Resistance as a Function of HIV Reverse Transcriptase Fidelity
and Total-Body HIV Virion Burden Predicts Sharp Non-linear Superiority of Three-
drug Over Two-drug Therapeutic Regimens.4'h Conference on Retroviruses and
Opportunistic Infections, Washington, DC. 406.
1997 Race, 8., Reimann, K., Letvin, N. and Japour, AJ. Recurrence of Trimethoprim-
Sulfamethoxazole TMP-SMX Hypersensitivity Following Initiation of Protease
Inhibitor (PRI) in Patients with Advanced HIV-1. 4'h Conference on Retroviruses and
Opportunistic Infections, Washington, DC. 535.
1997 Sun, 8., Xu, Y., Hsu, A., Japour, AJ., Korneyeva, M., Molla, A., Kempf, D., Leonard,
J., and The Ritonavir-Saquinavir Study Group. Predictability of Response to Ritonavir-
Saquinavir (RTV-SQV) Combination Therapy. Keystone, April.
1997 Molla, A., Korneyeva, M., Chernyavskiy, T., Colgrove, R., Chung, p., Japour, AJ.,
Mellors, J., Xu, Y., Rode, R., Hsu, A., Granneman, G., Kempf, D., Leonard, J., Sun, E.
and M96-462 Study Team. Characterization of HIV-l Protease (PR) Mutations,
Compliance, and Drug Concentrations in Patients Who Have an HIV RNA Rebound on
Ritonavir-Saquinavh (RTV-SQV).International Workshop on HIV Drug Resistance,
Treatment strategies and Eradication, St. Petersburg, Florida, 83, June 25-29.
1997 Welles, S., Pitt, J., Colgrove, R., Mclntosh, K., Chung, p., Colson, A., Lockman, S.,
Davenny, K., Fowler, M., Hansen, I., Landesman, S., Moye, J., Rich, K., Zorilla, C.,
Japour, AJ. Molecular ZDV-Resistance and the Risk of Perinatal HIV-l Transmission
in the Women & Infants Transmission Study (WITS).Infectious Disease Society of
America, San Francisco, California, September.
1997 Lal, R., Hsu, A., Chen, P., Dennis, S., El Shourbagy, T., Locke, C., Lam, W., Japour,
AJ., Leonard, J., Granneman, G.R., Sun, E. Single Dose Pharmacokinetics of ABT-378
in Combination with Ritonavir. 37'h ICAAC. September 28-October l.
1997 Gisolf,8., Colebunders, R., Van Wanzeele, F., Van Der Ende, M., Koopmans, p.,
Portegies, P., Hoetelmans, R., Japour, AJ., Ward, P., De Wolf, F., Danner, S., on
behaH of the Prometheus Study Group. Treatment with Ritonavir/Saquinavir Versus
Ritonavir/Saquinavir/Stavudine. Sixth European Conference on Clinical Aspects and
Treatment of HIV Infection. Hamburg, Germany,354, October.
1995 Japour, AJ., Lenora, J., Meehan, P., Clax, P., Connor, J., Pollard, R., Mclaren, C.,
Johannesson, N., Erice, A., Cooney, 8., Holden-Wiltse, J., Hussey, S., Walesky, M.,
Wood, K., Booth, D., Purdue, L., Greenspan, D., Kasdan, P., Basiakos, y., Timpone, J.,
Pettinelli, c. and Crumpacker, c. A Phase I study of the safety, Tolerance and
Pharmacokinetics of Combination Didanosine/Ribavirin for HIV Disease (ACTG 231).
2nd National Conference on Human Retroviruses, Washington, D.C.102.
1995 Welles, S., Jackson, J., Yen-Lieberman, B., Demeter, L., Japour, A., Johnson, V.,
Kuritzkes, D., D'Aquila, R., Reichelderfer, P., Richman, D., Reichman, R., Mclaren, C.,
Todd, J., Kwok, S., Fischl, M., Dolin, R. and Crumpacker, C. prognostic Capacity of
Plasma HIV-1 RNA Copy Number in ACTG 116,4.. 2nd National Conference on Human
Retroviruses, Washington, D.C. 96.
1995 Japour, AJ., Drosopoulos, W., Katapodis, N., Chung, P.H., Kew, y., prasad, V.
Saturation Mutagenesis of the HIV-1 RT b3- b4 Hairpin Reveals Novel Mutations
Conferring Dideoxynucleoside Triphosphate Resistance. Fourth Workshop on Viral
Resistance, Annapolis, Maryland.
1995 Japour, AJ. & Pitt, J. Maternal-Infant Transmission of Zidovudine-Resistant (ZDVR)
HIV-1. Infectious Diseases Society of America Meetings, San Francisco, California.
1995 Japour, AJ., Kim, S., Greene, R., Joseph, R., Chatis, P. Clinical HIV-I Isolares
Displaying ddl-Resistance in Culture May be Unstable With Serial Passage. 35'h
lnterscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco,
24
23
22
2t
20
19
18
t7
Japour-CV_ AUG-2014 P. 14
32
t6
15
I4
California, 1280.
1995 Chatis, P.A., Brewster, F., Joseph, R.A., Greene, R.A., Japour, AJ. A Direct Method
for Detection of Nevirapine Resistance in HIV-1 Clinical lsolates. 35'h Interscience
Conference on Antimicrobial Agents and Chemotherapy. San Francisco, California,
T28T.
1995 Demeter, L., Sannerud, K., Mayers, D., Fitzgibbon, J., Sylvester, S., Arens, M., Fisher,
E., Shafer, R., Zhao, Y., Huang, D., Reichelderfer, P., Johnson, V.A., Richman, D.,
Rasheed, D., Kuritzkes, D., and Japour, AJ., for the ACTG Genotypic Resistance
Working Group. lnterlaboratory Concordance of DNA Sequence Analysis of the HIV-1
Reverse Transcriptase. 35'h Interscience Conference on Antimicrobial Agents and
Chemotherapy, San Francisco, California, 12 84.
1995 Erice, A., Brambilla, D., Demeter, L., Penas, J., Brewster, F., Stellrecht, K.,
Reichelderfer, P., Mayers, D., and Japour, AJ., for the ACTG Virology Committee.
Zidovudine (ZDV) Susceptibility Screening Assay for Clinical HIV Isolates.35'h
Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco,
California, 1285.
1994 Greene, R.A., Japour, A., Joseph, R., Kasila, P., Litt, G., Chatis, p. A Direct Method for
Detection of ddl Resistance in HIV-1 Clinical Isolates.34th Interscience Conference on
Antimicrobial Agents and Chemotherapy, Orlando, Florida, October, 12 I 4.
1993 Japour, AJ., Chatis, P., Kim, S., Crumpacker, C.S. HIV-1 DDl-Resistance Overcome
With Combination DDl/Ribavirin. [X International Conference on AIDS, Berlin,
Germany, Abstract #Po A26-O640, June.
1993 Japour, AJ., Fiscus, S., Mayers, D., Reichelderfer, P., Kuritzkes, D. Microtiter
Modification of the MT-2 Syncytia Assay.IX International Conference on AIDS,
Berlin, Germany, PoB4l -2484, June.
1993 D'Aquila, R., Johnson, V., Kuritzkes, D., Japour, AJ., Crumpacker, C., Richman, D.
HIV-1 Drug Resistance and Syncytium-lnducing Phenotype: Associations With Disease
Progression Among ACTG 1l68/117 Subjects. IX International Conference on AIDS,
Berlin, Germany, PoB26-2O46, June.
1993 Lan, Y., Japour, AJ., Kim, S., Crumpacker, C.S., Welles, S.L., Mclntosh, K. A Rapid,
Direct Test for Zidovudine Susceptibility in Clinical Isolates of Human
Immunodeficiency Virus Type 1 (HIV-l) From Infected Children. IX International
Conference on AIDS, Berlin, Germany, Po8262048, June.
1993 Kuritzkes, D.R., welles, S., Johnson, v.A., crumpacker, c.s., DeGruttola, v., Japour,
AJ. The ACTG l168/117 Virology Resistance Team. "Baseline Prevalence and
Clinical Significance of Zidovudine (ZDY) Resistance Mutations in HIV-1 Isolates
From Patients in ACTG Protocol 1l6Bi 1 17. Third Workshop on Viral Resistance,
Washington, D.C., September.
1992 Japour, AJ., Kuritzkes, D., Johnson, V., Mayers, D., Beckett, L., Arduino, J.M.,
D'Aquilia, R., Crumpacker, C.S. Consensus Protocol to Measure Antiviral Resistance in
Clinical HIV-l Isolates. VIII International Conference on AIDS, Amsterdam, The
Netherlands, Abstract #PoA 2484, July .
1992 Johnson, V., Balfour, H., Beckett, L., Cheseboro, B., Crumpacker,C.,Haberzetti, C.,
Japour, AJ., Katzenstein, D., Kuritzkes, D., Mayers, D., Mclntosh, K., Rangan, S.,
Reichman, R., Richman, D., Scott, W., D'Aquila, R., AIDS Clinical Trials Group
Virology Committee Virus Resistance Working Group. Inter-Laboratory Variability of
Anti-HIV-1 Susceptibility Testing. VIII International Conference on AIDS, Amsterdam,
The Netherlands, Abstract #PoA23I0, July.
1992 Japour, AJ., Kim, L., Chatis, P.A., Beckett, L., Arduino, J.M., Ecto, L., Chapman, B.,
Crumpacker, C.S. Serial HIV-1 ZDY and DDI Susceptibility in a Cohort of Subjects
I3
t2
u
10
Japour-CV-AUG-2014 P. 15
33
2006
Enrolled in Three Antiviral Trials. VtrI International Conference on AIDS, Amsterdam,
The Netherlands, Abstract #PoB3572, Jul
Japour, AJ., Mayers, D., Arduino, J.M., Beckett, L., Crumpacker, C.S. ZDY & ddl
Susceptibility Correlates in Clinical HIV-I Isolates. Infectious Diseases Society of
America Annual Meeting, Anaheim, California.
Japour, AJ., Chatis, P.A., Kim, L., Crumpacker, C.S. HIV Susceptibility Testing in
AIDS Clinical Trials. Seventh International Q$gpLgg o, AIDS,Ilorencg, Ita p,
Japour, AJ., Chatis, P.A., Eigenrauch, H., Kim, L., Crumpacker, C.S. ddl Potentiation
Ribavirin. seventh International conference on AIDS, Florence,Italy, June.
Japour, AJ., Eigenrauch, H.A., Chatis, PA., Crumpacker, C.S. AzT-Resistant HIV
Detection by RNA-RNA Hybridization. Sixth International Conference on AIDS, San
Francisco, California, USA. Abstract #F.A.336, June.
Japour A.rMassaro, M., Nordstrom D., Silberman C., Provost D.,phase IV trial,
observational study or patient registry: which? when? why? at http://www.ppdi.com
62 7t2014 sov ALD I@ ( sofosbuv ir ) Roundtable Dis cus si.on : c linical c onsiderations in
Paticnt Managemenr, Coral Gables, FL
6l 4t20t4 Transforming the Treatrnent Paradigm, Review of sovALDl@(sofosbuvir), Miami
Beach, FL
60 3t20t4 Once Daily Olysio (simeprevir) 150 mg- Clinical Overview, Palm Harbor, FL
59 3/2014 once Daily olysio (simeprevir) 150 mg- clinical overview, Florida center for
Gastroenterology, Largo, FL
58 3t2014 Once Daily Olysio (simeprevir) 150 mg- Clinical Overview, St. Petersberg, FL
57 3t2014 once Daily olysio (simeprevir) 150 mg- clinical overview, GastroHealth, Miami,
FL
56 2t20r4 Once Daily Olysio (simeprevir) 150 mg- Clinical Overview, Tampa, FL
55 y20r4 Once Daily Olysio (simeprevir) 150 mg- Clinical Overview, Palm Beach, FL
54 u2014 Once Daily Olysio (simeprevir) 150 mg- Clinical Overview, Punta Gorda, FL
53 u20t4 Once Daily Olysio (simeprevir) 150 mg- Clinical Overview, Savannah, GA
52 12t20t3 Once Daily Olysio (simeprevir) 150 mg- Clinical Overview, Orlando, FL
51 t2t20t3 Once Daily Olysio (simeprevir) 150 mg- Clinical Overview, Miami Beach, FL
50 t2t20t3 Once Daily Olysio (simeprevir) 150 mg- Clinical Overview, Bonita Springs, FL
49 tu20t3 Hepatitis c: Past, Present, Future, Borinquen Medical centers of Miami Dade,
Miami, FL
48 9t2013 Hepatitis c Medications & side Effects, Hepatitis c support Group, Miami Beach,
FL
47 8t20t3 Hepatitis c: Past, Present, Future, Mount sinai Medical center Medical Grand
Rounds CME Program, Miami Beach, FL
Japour_CV_AUG-2014 P. 16
34
46 7t20t3 Treatment-Naive Adult Patient with Chronic HCV Gl Infection who has
Compensated Liver Disease, Miami, FL
45 6t2013 Addressing Chronic Hepatitis C in Primary Care: Integrating Recent Medical
Recommendarions, Borinquen Medical Center, Miami, FL
44 5t2013 Addressing chronic Hepatitis c in Primary care: Integrating Recent Medical
Recommendations,Famtly Care at Bardmoor, Largo, FL
43 5t2013 Addressing Chronic Hepatitis c in Primary Care: Integrating Recent Medical
Recommendations, lndian Shores, FL
42 4t20t3 Treatment-Naive Adult Patient with Chronic HCV Gl Infectionwho has
Compensated Liver Disease, Fort Myers, FL
4t 4120t3 Today's Chronic Hepatitis C Patient: VirallPatient Factors and predicting
Disease Progression, Digestive Care Center, North Miami, FL
40 3t2013 Treatment-Naive Adult Patient with Chronic HCV Gl Infection who has
Compensated Liver Disease, Macon, GA
39 3t2013 Addressing chronic Hepatitis c in Primary care: Integrating Recent Medical
Recommendarions, Athens, GA
38 3t2013 Current Treatments for Chronic HCV: Translating Clinical Studies into Clinical
Practice, Absolute Care, Atlanta, GA
37 2t2013 Current Treatments for Chronic HCV: Translating Clinical Studies into Clinical
Practice,Tampa General Medical Group, Tampa. FL
36 2t20t3 Treatment-Naive Adult Patient with Chronic HCV Gl Infection who has
Compensated Liver Disease, Miami Beach, FL
35 U2013 Treatment-Naive Adult Patient with Chronic HCV Gl Infection who has
Compensated Liver Disease, Melbourne, FL
34 y20t3 Today's chronic Hepatitis c Patient: virallPatient Factors and predicting
Disease Progression, Daytona, FL
33 t2t2012 Advanced Liver Disease in Chronic HCV: Strategies to Help and Monitor
Patients, Liver Transplant Unit at Broward General Medical Center, Fort
Lauderdale, FL
32 tU20t2 Current Treatmentsfor Chronic HCV: Translating Clinical Studies into Clinical
Practice,Triple O Medical, Palm Beach, FL
3l ty2012 Current Treatments for Chronic HCV: Translating Clinical Studies into Clinical
Practice, Central Indiana Gastroenterology Group, Indianapolis, IN
30 tU20t2 Current Treatmentsfor Chronic HCV: Translating Clinical Studies into Clinicai
Practice,Private Practice, Palm Beach, FL
29 IU20t2 Current Treatments for Chronic HCV: Translating Clinical Studies into Clinical
Practice, Gastroenterology Care Center, Miami, FL
28 tot20t2 Current Treatments for Chronic HCV: Translating Clinical Studies into Clinical
Practice, Digestie Medicine Associates, Miami, FL
27 tot20t2 Current Treatments for Chronic HCV: Translating Clinical Studies into Clinical
Practice,University of Maryland Medical Center, Baltimore. MD
26 9t2012 Current Treatmentsfor Chronic HCV: Translating Clinical Studies into Clinicil
Practice, St. Petersburg, FL
25 8/20t2 Management of chronic Hepatitis c Infection, one patient at aTime, west palm
Beach, FL
24 7t2012 Current Treatmentsfor Chronic HCV: Translating Clinical Studies into Clinical
Practice,Long Beach, CA
23 7t20r2 Current Treatments for Chronic HCV: Translating Clinical Srudies into Clinical
Practice, Los Angeles, CA
Japour_CV_AU G -2014 P. 17
35
22 5t20t2 Management of Chronic Hepatitis C Infection, One Patient at a Time, Miami
Beach, FL
21 5t20t2 Current Treatrnents for Chronic HCV: Translating Clinical Studies into Clinical
Practice, Augusta, GA
20 9t20It Jackson North Medical Center Obstetrics & Gynecology, September 2OlI,
Hepatitis C Diagnosis and Treatment in Pregnant Women-New Directions in
Hepatitis C treatment
l9 8t20tt Jackson North Medical Center Radio Show, August 20ll, Hepatitis C in the
Community-Epidemiology, Diagnosis a& New Treatment Directions in Hepatitis C
18 U20tt Florida International University College of Medicine , Syphilis
t7 10/2010 BioFlorida Annual Conference, Ft. Lauderdale, FL, Keynote Address, Policy
Implications for An Evolving Biosciences and Health Care Industry.
16 oIt20t0 Florida International University College of Medicine , Syphilis
l5 tu2009 American Bar Association, AIDS Coordinating Committee, New HIV Infections in
the United States.
t4 L2t2N9 Florida International University College of Medicine , Infectious Diseases as
Agents of Bioterrorism
13 02t2009 Northwestern University, Keynote Address, Alumni Dance Marathon Dirrrret,The
HMNDS Battle in tlu 21" Century.
t2 1ll2008 Cruise Line International Association, Miami, FiL, Avian InJluenTa
ll r1t2007 Cruise Line International Association, Miami, FL, Avian Influenza
t0 2W7 Seatrade, Miami Beach, FL, Avian Intluenza
9 2007 Miami Beach City Hall, Miami Beach, FL, Avian Influenla- History and Present
Threat
8 08t2006 Centers for Disease Control, Florida department of health, Miami-Dade County
Health Department, International Conference of Cruise Lines, Royal Caribbean
Cruises Avian Influenza (HSNl Business Continuity and Shipboard Preparedness
Planning)
7 2006 International Conference of Cruise Lines, Avian Influenza- History and Present
Threat
6 2000,-2003 Academic Medical Centers in the US, Where Science Meets Ethics in Clinical
Trials: The HIV/NDS Paradism
5 r996-2002 Harvard HMME Course, Antiviral Drug Resistance or Where Science Meets
Ethics in Clinical Trials: The HIVINDS Paradigm
4 t99s-2002 lnfectious Diseases Training Program, Beth Israel-Deaconess Medical Center,
Antiretroviral Thcrapy for HIV Disease
3 1992-199s Harvard Medical School, clinical Pharmacology & Therapeutics course HST 350,
Molecular Structure of Drug-Resistant HIV-l
2 1990-1995 Beth Israel Hospital Medical Housestaff Lecture Series , syphilis in the AIDS Era
I 1989-1995 Harvard Medical school, Infectious Diseases course 5l3lviJ, syphilis in the NDS
Era
Japour-CV_AUG-2014 P. lE
36
1998
1997
1997
t997
Japour, A., Murphy, R., Hicks, C., Eron, J.,Yetzer,E., Hammer, S., Orth, K.
Safety & Efficacy of ABT-378/Ritonavir in Antiretroviral-Naive HIV Patients:
Preliminary Phase II Results. 12s world AIDS conference, Geneva, Switzerland,
June 28
zoilla,c., Japour, A.J. Molecular ZDV-Resistance and the Risk of perinatal HIV-
I Transmission in the women & Infants Transmission Study (WITS).Infectious
Disease Society of America, San Francisco, California, September
Race,8., Adelson-MittyrJ.rBarlam, T., and Japour, A.J. Focal Inflammatory
Lymphadenitis (FIL) and Fever Following Initiation of Protease Inhibitor (PRI) in
Patients with Advanced HIV-I Disease.4'h conference on Retroviruses and
Opportunistic Infections, Washington, DC. 352
colgrove, R., Japour, A.J. Mathematical Modeling of within-patient Evolution of
HIv-l Antiretroviral Resistance as a Function of HIV Reverse Transcriptase
Fidelity and Total-Body HIV Virion Burden Predicts Sharp Non-linear Superiority
of Three-drug Over Two-drug Therapeutic Regimens.4'h Conference on
Retroviruses and Opportunistic Infections, Washington, DC. 406
Race, E., Reimann, K., Lrtvin, N. and Japour, A.J. Recurrence of Trimethoprim-
Sulfamethoxazole TMP-SMX Hypersensitivity Following Initiation of Protease
Inhibitor (PRI) in Patients with Advanced HIV-1. 4'h Conference on Retroviruses
and Opportunistic Infections, Washington, DC. 535
Welles, S., Pitt, J., Colgrove, R., Mclntosh, K., Chung, P., Colson, A., Lockman,
S., Davenny, K., Fowler, M., Hansen,I., Landesman, S., Moye, J., Rich, K.,
A Double-blind, Rando mized, Placebo-controlled,
Multicenter Study Assessing the Impact of Additional
LDl-Cholesterol Reduction on Major Cardiov asc ular
Events When AMG 145 is Used in Combination with
Statin Therapy in Patients with Clinically Evident
Cardiovascular Disease
A Multi-Center, Prospecti ve, Rando rnized,Double-B lind,
Placebo-Controlled, Parallel-Group Study to Evaluate the
Effect of AMR101 on Cardiovascular Disease and
Mortality in Hypertriglyceridemic Patients with
Cardiovascular Disease or at High Risk for Cardiovascular
Disease: REDUCE-IT (Reduction of Cardiovascular Events
with E?A-Intervention Trial) Amarin Pharma, Inc
SABA: A study of factors that affect adherence to HIV
therapy and safer sex behaviors a.mong women in the
Miami-Dade County's AIDS Drug Assistance Program
FOCUS: A study of factors that affect adherence to HIV
Amarin Pharma,
Inc.
Miami-Dade
County Health
Department AIDS
Program
Miami-Dade
20t2-2013
2007-200/9
2004-2007
Japour_CV_AU G -2014 P. 19
37
6
5
therapy and safer sex behaviors among men who have sex
with men in the Miami-Dade Counff's AIDS Drug
Assistance Program.
Intravenous Infusion in HlV-Positive Patients
Maiernal-Infant Transmission of ZDV-Resistant HIV-l in
the Women and Infants Transmission Study
Maternal-Infant Transmission of ZDV-Resistant HIV- I
HIV-I Zidovudine and Didanosine Resistance Detection
Drug Resistant HIV-I RT-Molecular Structure and
Function
Detection of HIV RNA in Patients Blood
County Health
Department AIDS
Program
Hybridon
NIH-NIAID
Pediatric AIDS
Foundation
DuPont-NEN Life
Sciences
MH-NIAID
American
Foundation for
AIDS Research
1996
1995-1999
tgg4-tgg6
1994-1996
1992-1996
t989-1992
3 Biological Response Toolkit for Florida Hospitals.
Development, production and training kit.
2 Harvard Advanced Technical Laboratory Adult AIDS
Clinical Trial Group
Harvard/Boston AIDS Clinical Trial
Elizabeth Race, M.D. (Fellowship)
Clinical Investigator Training Program
Florida Department
of Health
(subcontract to
Jackson Health
System)
NIH.NIAID
NIH-NIAID
Harvard/MIT
Health Sciences
Technology
2006-2007
1995-1996
tgg}-tgg6
1996-1998
Physician-Scientist Award, National Institute of Allergy and Infectious Disiasei
Japour_CV_AA G -2014 P . 20
38
Scholar for the American Foundation for AIDS Research
Microbes, Infection and
Immunology
BMS63OO 2009-2013
Amy Colson, Beth Israel Hospital, Medical Resident, Boston, MA
Title: Maternal-Infant HIV Drug Resistance Transmission
Publications:. Welles, S.L., Pitt, J., Colgrove, R., Mclntosh, K., Chung, PJI., Colson, A.,
Lockman, S., Fowler, M. G., Hanson, C., Landesman, S., Moye J., Rich, K.C.,
Zorrilla, C., Japour, A. J. HIV-l Genotype Zidovudine Drug Resistance and the
Risk of Maternal-Infant Transmission In the Women and Infant Transmission
study. NDS 14:263-272. Welles, S., Pitt, J., Colgrove, R., Mclntosh, K., Chung, P., Colson, A.,
Lockman, S., Davenny, K., Fowler, M., Hansen, [., Landesman, S., Moye, J.,
Rich, K., Zorilla, C., Japour, AJ. Molecular ZDV-Resistance and the Risk of
Perinatal HIV-1 Transmission in the Women & Infants Transmission Study
(WITS). Infectious Disease Society of America, San Francisco, California,
September
Shahin Lockman, Beth Israel Hospital, Medical Resident, Boston, MA
Title: Maternal-Infant HIV Drug Resistance Transmission
Publiccation:. Welles, S.L., Pitt, J., Colgrove, R., Mclntosh, K., Chung, P.H., Colson, A.,
Lockman, S.rFowler, M. G., Hanson, C., Landesman, S., Moye J., Rich, K.C.,
Zonilla, C., Japour, A. J. HIV-1 Genotype Zidovudine Drug Resistance and the
Risk of Maternal-Infant Transmission In the Women and Infant Transmission
study. AIDS 14:263-272. Welles, S., Pitt, J., Colgrove, R., Mclntosh, K., Chung, P., Colson, A.,
Lockman, S., Davenny, K., Fowler, M., Hansen, I., Landesman, S., Moye, J.,
Rich, K., ZorilLa,C., Japour, AJ. Molecular ZDV-Resistance and the Risk of
Perinatal HIV-I Transmission in the Women & Infants Transmission Study
(WITS). Infectious Disease Society of America, San Francisco, California,
Japour_CV_AU G -2014 P, 2l
39
1998 Scott Brun, Physician Rotation Program, Abbott Laboratories Professional Development
Program
Title: Phase I/II Clinical Research Studies in HIV
Publications:. Hicks, C., King, M., Brun, S., Real, K., Murphy, R., Eron, J., Thommes, J.,
Gulick, R., Glesby, M., Thompson, M., White, C., Benson, M., Albrecht, M.,
Kessler, H., Hsu, A. Bertz, R., Kempf, D., Japour, A., & Sun, E. ABT-
378/Ritonavir (ABT-378/R) in Antiretroviral Naive HIV + Patients: 48 Weeks.
7th European Conference on Clinical Aspects and Treatment of HIV Infection.
Lisbon, Portugal, October 23-27. Bertz,R., Lam, W., Brun, S., Kumar, G., Fields, C., Orth, K., Jennings, J., Hsu,
A., Granneman, R., Japour, A., Sun, E. Multiple-Dose Pharmacokinetics (PK) of
ABT-378/Ritonavir (ABT-378/r) in HIV+ Subjects.3g'h ICAAC Conference on
Antimicrobial Agents and Chemotherapy, September 26-29. Murphy, R., King, M., Brun, S., Orth, K., Hicks, C., Eron, J., Thommes, J.,
Gulick, R., Thompson, M., White, C., Benson, C., Hammer, S., Kessler, H.,
Bertz, R., Hsu, A., Kempf, D., Sun, 8., Japour, A. ABT-378/ritonavir Therapy in
Antiretroviral-Narve HIV-I Infected Patients for 24 weeks. 6'b Conference on
Retroviruses and Opportunistic Infections, January 31 - February 4
1995-96 Robert Colgrove, Beth IsraeiHospital, Boston, MA
Title: Mathematical Modeling of HIV Drug Resistance
Publication:
' Colgrove, R., Japour, A. A Combinatorial Ledge: Reverse Transcriptase
Fidelity, Total Body Viral Burden, and the Implications of Multiple-Drug HIV
Therapy for the Evolution of Antiviral Resistance. Antiviral Res 4l,45-56
' Colgrove, R., Japour, AJ. Mathematical Modeling of Within-Patient Evolution
of HIV-I Antiretroviral Resistance as a Function of HIV Reverse Transcriptase
Fidelity and Total-Body HIV Virion Burden Predicts Sharp Non-linear
Superiority of Three-drug Over Two-drug Therapeutic Regimens. 4'h Conference
on Retroviruses and Opportunistic Infections, Washington, DC.406
Title: Maternal-Infant HIV Drug Resistance Transmission
Publication:. Colgrove, R.C., Pitt, J., Chung, P.H., Welles, S.L., Japour, AJ. Selective
Vertical Transmission of HIV-1 Antiretroviral Resistance Mutations . AIDS
12:2281-2288. Colgrove, R., Pitt, J., Japour, A., Welles, S. Evolutionary Hotspot around RT
Codon 215 Evolves During Zidovudine Exposure. 6'h Conference on
Retroviruses and Opportunistic Infections, January 3l - February 4. Colgrove, R., Piff, J., Chung, P., Welles, S., Japour, AJ., Harvard Medical
School, Boston, Massachusetts, Columbia University, and University of
Minnesota, Minneapolis, Minnesota. Selective Vertical Transmission of HIV-1
Zidovudine Resistance Mutations. 5'h Conference on Retroviruses and
Opportunistic Infections, Chicago, Illinois
1995-96 Jennifer Adelson-Mitty, Beth Israel Hospital, Boston, MA
Title: HIV Immune Reconstituion Syndrome
Publication:. Race, E., Adelson-Mitty, J., Barlam, T., Japour, A.J. Focal Inflammatory
Lymphadenitis (FIL) and Fever Following Initiation of Protease Inhibitor (PRI)
Japour-C Y-AU G -?,014 P . 22
40
rn Patients with Advanced HIV-1 Disease. Lont'et 351:252-2-5-5
1994-96 Elizabeth Race, Beth Israel Hospital, Boston, MA
Title: HI\z Immune Reconstituion Svnclrome
Publication:
' Race, E.. Adelson-Mitty. J.. Barlam. T.. Japour. A.J. Focal Inflammatory
Lymphadenitis (FIL) and Fever Follorvine Initiation of Protease Inhibiror (PRI)
in Patients with Advanced HIV-1 Disease. Lancer 351:252-255
Race,8,., Reimann, K., Letvin. N. and Japour. A.J. Recurrence of Trimethoprim-
Sulfamethoxazole TMP-SMX Hypersensitivity Follorving Initiation of Protease
Inhibitor (PRI) in Patients lr'ith Advanced HIV- 1 . 4'i' Conference on Retroviruses
and Opportunistic Infections. Washington. DC. 5-35
Race, E., Adelson-Mitty. J.. Barlam. T.. and Japour. A.J. Focal Inflammatory
Lymphadenitis (FIL) and Fever Follorving Initiation of Protease Inhibitor (PRI)
in Patients r,vith Advanced HIV-1 Disease.4'r'Conference on Retroviruses and
Opportunistic Infections. Washington, DC. 3-52
SERVICE DETAILS
Editorial Boards
Date Editorial Board
I r 1995-96 i Associate Editor, AIDS Clinical CzLre published by the Massachusetts Medicali __ ___t rgsrqry
Revlewing Duties: Jounal
6
5
4
3
2
I
l0
9
8
7
6
5
20t2
2002-03
1995-03
1995-2003
r994-98
r994-2003
Future Virology- ad hoc
Clinical Infectious Diseases- ad hoc
AIDS- ad hoc
Journal of Infectious Diseases- ad hoc
Journal of Clinical Microbiology- ad hoc
Journal of AIDS- ad hoc
Assay Development committee, virology Quality Assurance Program NIH-DAIDS
NIH ACTG Adult Scientific Virology Committee, Core Member
NIH ACTG Genotype Sequencing Swat Team, Core Member
NIH ACTG HIV Resistance Screening Assay Srvat Team, Chair
Assay Development Committee, NIH AIDS Clinical Trial Group; Vice Chair
Beth Israel Hospital clinical Research Center Scientific Advisory committee
Grant Reviews
No Date Agencies
1993-2010 Ad hoc Reviewer, National Institute of Allergy and Infectious Diseases,
National Institutes of Health, Bethesda, MD
Conference Committees-AlDS Ctinical Trials Group (ACTG)
No Date Conference Information
1996
t994-96
t994-95
r994-95
1994-95
t993-96
Japour_CV_ LUG-2014 P. 23
41
4
3
2
1
11
l0
9
8
7
6
5
4
3
2
1
1993-9s
1993-94
1990-9s
1990-93
NIH ACTG Primary Infection Committee Phase IVIII Working Group
NIH ACTG MT-zSwat Team, Chair
NIH ACTG Virology Committee
NIIH ACTG HIV Resistance Working Group, Core Member
Hepatology Speaker's Bureau, AbbVie, Nonh Chicago,IL
Hepatitis C Speaker's Advisory Board, Bristol-Myers Squibb, plainsboro, NJ
HIV Clinical Advisory Board, Bristol-Myers Squibb, Plainsboro, NJ
Hepatitis Clinical Advisory Board, Gilead Pharmaceuticals, Foster City, CA
Hepatitis C Speaker's Bureau, Janssen Pharmaceutical Company
Hepatitis C Speaker's Advisory Board, Boehringer Ingelheim GmbH
Pharmaceuticals, Ridgefield, CT
Hepatitis C Speaker's Advisory Board-USA, Merck & Company, Blue Bell, pA
Health Advisory Board, City of Miami Beach
Scientific Advisory Board, ImmunoGenetix, Inc., Lenexa, KS
American Bar Association, AIDS Coordinating committee, Health Care Advisory,
Washington, D.C.
Homeless Committee, City of Miami Beach, Miami Beach, FL
Republican Primary Candidate, State of Florida House of Representatives, District
to7
Cultural Arts Council, City of Miami Beach, Miami Beach, Fl
community Development Advisory council, city of Miami Beach, Miami Beach, FL
Florida Medical Association, Tallahassee, FL
Miami Beach Bar Association, Miami Beach, FL
Miami Beach Chamber of Commerce, Miami Beach, FL
Scientific Advisory Board, S equoia Pharmaceuticals, Inc., Gaithersburg, MD
Finc Arts Board, CltV of Miami Beach, Miami Beach, FL
Scientific Advisory Board, PPD Inc. Government Group, Wilmington, NC
Miami Beach Latin Chamber of Commerce, Miami Beach, FL
Board of Directors, Open Hand Chicago, Chicago, [L
Core Laboratory
Beth Israel Hospital- Harvard Medical School, HIV Endowment Fund
23 20t4
22 2014
21 2014
20 20t4
19 20t3-
Present
18 20t3
t7 20tt-
Present
16 2011-2013
15 20tt-
Present
14 2009-
Present
13 20to
12 2009-10
2007-to
2006
2004-tt
2006-08
2006.o7
2004-06
- 2004-06
2004-05
2W3-O7
1999-O2
1989-96 Blackstone - Franklin Square Neighborhood Association, Boston, MA
Scientific Director, Harvard-Thorndike General Clinical Research Center Molecular
1995
Japour_CY_AU G -2014 P. 24
42